<html lang="en" class="pb-page js" data-request-id="94d64a8083a901a6-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d64a8083a901a6-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/QqGgkWJsXXpwlD-KeO0ScQycFgGqnNnLQhYZpGPixfb-DVn4KrHAM9u9dpMJmv5h_f8w7zbqOB19TGIUqfCgPA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d64a8083a901a6-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.5805367351717644"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Urology/Prostate Disease|Hematology/Oncology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Urology/Prostate Disease General|Treatments in Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2002788","title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","category":"Research","type":"Original Article","topics":"Urology/Prostate Disease General|Treatments in Oncology","specialties":"Urology/Prostate Disease|Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-09-24T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Urology/Prostate Disease|Hematology/Oncology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Urology/Prostate Disease General|Treatments in Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2002788","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Quick Take","title":"Avelumab for Advanced or Metastatic Urothelial Carcinoma","doi":"10.1056/NEJMdo005831","issueDate":"2020-09-24T00:00Z","age":"6Months-1990","isFree":"n","topics":"Urology/Prostate Disease General|Treatments in Oncology","viewType":"Full","specialties":"Urology/Prostate Disease|Hematology/Oncology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d64a8083a901a6-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma"><meta name="dc.Creator" content="Thomas Powles"><meta name="dc.Creator" content="Se Hoon Park"><meta name="dc.Creator" content="Eric Voog"><meta name="dc.Creator" content="Claudia Caserta"><meta name="dc.Creator" content="Begoña P. Valderrama"><meta name="dc.Creator" content="Howard Gurney"><meta name="dc.Creator" content="Haralabos Kalofonos"><meta name="dc.Creator" content="Siniša Radulović"><meta name="dc.Creator" content="Wim Demey"><meta name="dc.Creator" content="Anders Ullén"><meta name="dc.Creator" content="Yohann Loriot"><meta name="dc.Creator" content="Srikala S. Sridhar"><meta name="dc.Creator" content="Norihiko Tsuchiya"><meta name="dc.Creator" content="Evgeny Kopyltsov"><meta name="dc.Creator" content="Cora N. Sternberg"><meta name="dc.Creator" content="Joaquim Bellmunt"><meta name="dc.Creator" content="Jeanny B. Aragon-Ching"><meta name="dc.Creator" content="Daniel P. Petrylak"><meta name="dc.Creator" content="Robert Laliberte"><meta name="dc.Creator" content="Jing Wang"><meta name="dc.Creator" content="Bo Huang"><meta name="dc.Creator" content="Craig Davis"><meta name="dc.Creator" content="Camilla Fowst"><meta name="dc.Creator" content="Nuno Costa"><meta name="dc.Creator" content="John A. Blake-Haskins"><meta name="dc.Creator" content="Alessandra di Pietro"><meta name="dc.Creator" content="Petros Grivas"><meta name="dc.Description" content="Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistanc..."><meta name="Description" content="Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistanc..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-09-24"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2002788"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202009243831310"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2002788">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2002788">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2002788">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | NEJM">
        <meta property="og:title" content="Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2002788">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/a2d2c49d-075d-4dc9-862c-b393d6f5dc20/nejmoa2002788_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/a2d2c49d-075d-4dc9-862c-b393d6f5dc20/nejmoa2002788_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Platinum-based chemotherapy is standard-of-care first-line treatment for advanced
urothelial carcinoma. However, progression-free survival and overall survival are
limited by chemotherapy resistanc...">
        <meta name="twitter:description" content="Platinum-based chemotherapy is standard-of-care first-line treatment for advanced
urothelial carcinoma. However, progression-free survival and overall survival are
limited by chemotherapy resistanc...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2771">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2002788">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2002788">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2020.383.issue-13;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2002788;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2002788" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2002788" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2002788" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2002788" class="inputDoi"><input type="hidden" value="T. Powles and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:1218-1230" class="inputCitation"><input type="hidden" value="09-18-2020" class="inputEPubDate"><input type="hidden" value="September 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d64a8083a901a6-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas</span> <span property="familyName">Powles</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Se Hoon</span> <span property="familyName">Park</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eric</span> <span property="familyName">Voog</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Claudia</span> <span property="familyName">Caserta</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Begoña P.</span> <span property="familyName">Valderrama</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Howard</span> <span property="familyName">Gurney</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Haralabos</span> <span property="familyName">Kalofonos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+19</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Siniša</span> <span property="familyName">Radulović</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wim</span> <span property="familyName">Demey</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anders</span> <span property="familyName">Ullén</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yohann</span> <span property="familyName">Loriot</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Srikala S.</span> <span property="familyName">Sridhar</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Norihiko</span> <span property="familyName">Tsuchiya</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Evgeny</span> <span property="familyName">Kopyltsov</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cora N.</span> <span property="familyName">Sternberg</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joaquim</span> <span property="familyName">Bellmunt</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jeanny B.</span> <span property="familyName">Aragon-Ching</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel P.</span> <span property="familyName">Petrylak</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Laliberte</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jing</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bo</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Craig</span> <span property="familyName">Davis</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Camilla</span> <span property="familyName">Fowst</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nuno</span> <span property="familyName">Costa</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John A.</span> <span property="familyName">Blake-Haskins</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alessandra</span> <span property="familyName">di Pietro</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Petros</span> <span property="familyName">Grivas</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-19</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">September 18, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">1218</span>-<span property="pageEnd">1230</span></div><div class="doi">DOI: 10.1056/NEJMoa2002788</div><div class="core-enumeration"><a href="/toc/nejm/383/13"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">13</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DThomas%2BPowles%252C%2BSe%2BHoon%2BPark%252C%2BEric%2BVoog%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D13%26contentID%3D10.1056%252FNEJMoa2002788%26title%3DAvelumab%2BMaintenance%2BTherapy%2Bfor%2BAdvanced%2Bor%2BMetastatic%2BUrothelial%2BCarcinoma%26publicationDate%3D09%252F24%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2002788" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DThomas%2BPowles%252C%2BSe%2BHoon%2BPark%252C%2BEric%2BVoog%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D13%26contentID%3D10.1056%252FNEJMoa2002788%26title%3DAvelumab%2BMaintenance%2BTherapy%2Bfor%2BAdvanced%2Bor%2BMetastatic%2BUrothelial%2BCarcinoma%26publicationDate%3D09%252F24%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/8710cb5e-3311-41e6-9420-c01bec507080/nejmoa2002788.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2002788.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2002788" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2002788" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2002788.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab. The primary end point was overall survival, assessed among all patients who underwent randomization (overall population) and among those with tumors positive for programmed cell death ligand 1 (PD-L1). Secondary end points included progression-free survival and safety.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Among all 700 patients who underwent randomization, the addition of maintenance avelumab to best supportive care significantly prolonged overall survival as compared with best supportive care alone (control). Overall survival at 1 year was 71.3% in the avelumab group and 58.4% in the control group (median overall survival, 21.4 months vs. 14.3 months; hazard ratio for death, 0.69; 95% confidence interval [CI], 0.56 to 0.86; P=0.001). Avelumab also significantly prolonged overall survival in the PD-L1–positive population; overall survival at 1 year was 79.1% in the avelumab group and 60.4% in the control group (hazard ratio, 0.56; 95% CI, 0.40 to 0.79; P&lt;0.001). The median progression-free survival was 3.7 months in the avelumab group and 2.0 months in the control group in the overall population (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75) and 5.7 months and 2.1 months, respectively, in the PD-L1–positive population (hazard ratio, 0.56; 95% CI, 0.43 to 0.73). The incidence of adverse events from any cause was 98.0% in the avelumab group and 77.7% in the control group; the incidence of adverse events of grade 3 or higher was 47.4% and 25.2%, respectively.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02603432" target="_blank">NCT02603432</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo005831/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/079fc1f9-5fea-4149-8eae-0f107c472ff0/media/NEJMdo005831_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo005831/full/" class="ng-do-media_item-title-link">Avelumab for Advanced or Metastatic Urothelial Carcinoma</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 25s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Combination platinum-based chemotherapy is the standard of care for first-line treatment of advanced urothelial carcinoma in patients who are suitable candidates for platinum-based therapy.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Although chemotherapy is active (objective response in 40 to 50% of patients; disease control in 75 to 80%), most patients have disease progression within approximately 9 months, and the median overall survival is 14 to 15 months with cisplatin-based regimens and 9 to 10 months with carboplatin-based regimens among patients who are not suitable candidates for cisplatin-based therapy.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4 r5 r6" id="body-ref-r6" href-manipulated="true">2-6</a></sup> In several tumor types, maintenance therapy with an alternative agent after initial chemotherapy has been shown to prolong overall survival.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-1" href-manipulated="true" aria-label="Reference 7">7</a></sup> However, trials exploring this approach in advanced urothelial carcinoma with the use of targeted therapies or conventional chemotherapies have not shown prolonged overall survival.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10 r11" id="body-ref-r11" href-manipulated="true">8-11</a></sup></div><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Urothelial carcinoma is characterized by genomic instability, high programmed cell death ligand 1 (PD-L1) protein expression, DNA damage-response mutations, and a high tumor mutational burden, which are features associated with an increased response to immune checkpoint inhibitors in several cancer types.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13" id="body-ref-r13" href-manipulated="true">12,13</a></sup> Regulatory approvals of anti–PD-L1 and anti–PD-1 (anti–programmed cell death 1) antibodies have changed the treatment landscape for patients with advanced urothelial carcinoma,<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> including those who have disease progression after platinum-based chemotherapy, those who are not suitable candidates for first-line cisplatin-based therapy and have PD-L1–positive tumors, and those who are not suitable candidates for platinum-based therapy.</span><sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16 r17 r18 r19 r20 r21 r22 r23 r24 r25 r26" id="body-ref-r26" href-manipulated="true">15-26</a></sup> Because chemotherapy has various immune-priming effects and depletes immunosuppressive cells, maintenance therapy with a checkpoint inhibitor after first-line chemotherapy may result in enhanced antitumor activity while avoiding potential interactions, including cross-resistance and cumulative toxicity.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r27 r28" id="body-ref-r28" href-manipulated="true">7,27,28</a></sup> In a small, randomized, placebo-controlled, phase 2 trial of maintenance pembrolizumab (an anti–PD-1 antibody) after chemotherapy in patients with advanced urothelial carcinoma, progression-free survival was longer in the pembrolizumab group than in the placebo group.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup></div><div role="paragraph">Avelumab is an anti–PD-L1 antibody that has been approved in several countries for the treatment of locally advanced or metastatic urothelial carcinoma after disease progression during or after platinum-containing chemotherapy, on the basis of results from a large, phase 1b cohort (involving 242 patients) in which an objective response was observed in 16.5% of the patients and the overall survival at 2 years was 20.1%.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r30" id="body-ref-r30" href-manipulated="true">17,30</a></sup> We hypothesized that avelumab maintenance therapy would improve outcomes in patients who had received first-line platinum-based chemotherapy for advanced urothelial carcinoma.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patient Population</h3><div role="paragraph">In the JAVELIN Bladder 100 trial, we enrolled patients who had histologically confirmed, unresectable locally advanced or metastatic urothelial carcinoma; documented stage IV disease (according to the American Joint Committee on Cancer–International Union for Cancer Control tumor–node–metastasis system, 7th edition) that was measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, before the receipt of first-line chemotherapy; no disease progression (i.e., an ongoing complete response, partial response, or stable disease) after the receipt of four to six cycles of chemotherapy with gemcitabine plus cisplatin or carboplatin; and a treatment-free interval of 4 to 10 weeks since the last dose of chemotherapy. Other key inclusion criteria were an age of 18 years or more; an Eastern Cooperative Oncology Group performance-status score of 0 or 1 (on a 5-point scale, with higher numbers indicating greater disability); a recently obtained or archival tumor specimen; and adequate hematologic, hepatic, and renal function. Key exclusion criteria were the receipt of adjuvant or neoadjuvant systemic therapy within the preceding 12 months and a contraindication for or previous exposure to immune checkpoint inhibitors. Full eligibility criteria are provided in the <a href="#ap1">protocol</a> (available with the full text of this article at NEJM.org).</div></section><section id="sec-1-2"><h3>Trial Design</h3><div role="paragraph">In this international, open-label, phase 3 trial, patients were randomly assigned (in a 1:1 ratio) to receive either maintenance therapy with avelumab (at a dose of 10 mg per kilogram of body weight, administered intravenously every 2 weeks) plus best supportive care (avelumab group) or best supportive care alone (control group). To mitigate the occurrence of infusion-related reactions, an antihistamine and acetaminophen were administered approximately 30 to 60 minutes before the first four avelumab infusions. Best supportive care was administered according to local practice on the basis of the clinical judgment and the patient’s condition and included antibiotic agents, nutritional support, hydration, and pain management; other systemic antitumor therapy was not permitted, but palliative local radiotherapy for isolated lesions was acceptable.</div><div role="paragraph">Randomization was stratified according to the best response to first-line chemotherapy (complete or partial response vs. stable disease) and to the metastatic site when first-line chemotherapy was initiated (visceral vs. nonvisceral). The nonvisceral-site stratum included patients with unresectable locally advanced disease in addition to those with only nonvisceral disease, including bone metastasis. Patients continued treatment until disease progression, an unacceptable level of toxic effects, withdrawal of consent, or any other criterion for withdrawal occurred. Reductions in the avelumab dose were not permitted, but subsequent infusions could be omitted because of persisting adverse events. The primary objective of the trial was to assess the benefit of maintenance avelumab therapy over control therapy in prolonging overall survival among all the patients who had undergone randomization (overall population) and among patients with PD-L1–positive tumors (PD-L1–positive population).</div></section><section id="sec-1-3"><h3>Trial Oversight</h3><div role="paragraph">The trial was conducted in accordance with the ethics principles of the Declaration of Helsinki and with the Good Clinical Practice guidelines defined by the International Council for Harmonisation. All the patients provided written informed consent. The trial protocol and amendments were approved by an institutional review board or independent ethics committee at each participating center. An independent data and safety monitoring committee periodically reviewed safety data and reviewed the results of the interim analysis.</div><div role="paragraph">The trial was sponsored by Pfizer as part of an alliance between Merck (Darmstadt, Germany) and Pfizer. All the authors attest that they had access to the data and that they participated in the writing, reviewing, and editing of the manuscript. A professional medical writer funded by the sponsors assisted with manuscript preparation. The first author had final responsibility for the decision to submit the manuscript for publication. All the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol and the statistical analysis plan.</div></section><section id="sec-1-4"><h3>End Points and Assessments</h3><div role="paragraph">The primary end point was overall survival, which was assessed in both the overall population and the PD-L1–positive population. The inclusion of two primary populations was based on observations from previous studies of avelumab and other similar agents used as second-line treatment for advanced urothelial carcinoma, which suggested that response was higher among patients with PD-L1–positive tumor cells or immune cells than among patients with PD-L1–negative tumors.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r17 r18 r21" id="body-ref-r21-2" href-manipulated="true">16–18,21</a>,</sup></div><div role="paragraph">Secondary end points included progression-free survival, objective response (complete response or partial response, according to RECIST, version 1.1, as recorded from randomization until disease progression or death from any cause), time to response, duration of response, disease control (defined as complete response, partial response, non–complete response or non–progressive disease, or stable disease for ≥6 weeks, according to RECIST, version 1.1, as recorded from randomization until disease progression or death from any cause) as determined on the basis of blinded independent central review, and safety. Tumors were assessed according to RECIST, version 1.1. Imaging of the chest, abdomen, and pelvis was performed every 8 weeks for 12 months and then every 12 weeks until confirmed disease progression. Imaging of the head at baseline was required in patients with a history of brain metastases or in whom brain metastases were suspected. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</div><div role="paragraph">PD-L1 expression was assessed in tumor samples by means of the Ventana PD-L1 assay (SP263, Ventana Medical Systems). Patients were classified as having PD-L1–positive status if at least one of the following three criteria were met: at least 25% of tumor cells stained for PD-L1, at least 25% of immune cells stained for PD-L1 if more than 1% of the tumor area contained immune cells, or 100% of immune cells stained for PD-L1 if no more than 1% of the tumor area contained immune cells.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31" href-manipulated="true" aria-label="Reference 31">31</a></sup></div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We estimated that 668 patients, including 334 patients (50%) with PD-L1–positive tumors, would undergo randomization.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-3" href-manipulated="true" aria-label="Reference 21">21</a></sup> A one-sided test was performed against the null hypothesis that avelumab plus best supportive care would not be superior to best supportive care alone. The type I error rate was maintained at or below the one-sided level of 0.025 by allocating an alpha of 0.015 to the overall survival comparison in the overall population and an alpha of 0.01 to the overall survival comparison in the PD-L1–positive population. A two-look, group-sequential design with a Lan–DeMets (O’Brien–Fleming) alpha-spending function was used to preserve the overall type I error rate and determine efficacy boundaries.</div><div role="paragraph">The trial was to be considered to be positive if the stratified log-rank test for overall survival was significant in either primary population. For the primary analysis of overall survival in the overall population, we estimated that 425 deaths would provide the trial with 93% power to detect a hazard ratio of 0.7, using a one-sided log-rank test at a significance level of 0.015. For the primary analysis of overall survival in the PD-L1–positive population, we estimated that 219 deaths would provide the trial with 80% power to detect a hazard ratio of 0.65 using a one-sided log-rank test at a significance level of 0.01. The protocol prespecified the reporting of one-sided P values, but, in accordance with <i>Journal</i> policy, two-sided P values are reported.</div><div role="paragraph">An interim analysis was planned after 74% and 66.7% of the target events (deaths) were estimated to have occurred in the overall population and the PD-L1–positive population, respectively. Results of the interim analysis were reviewed on December 20, 2019, by the independent data and safety monitoring committee, which reported that the efficacy boundaries for overall survival in the overall population and the PD-L1–positive population (P&lt;0.0053 and P&lt;0.0014, respectively) had been crossed. Data from the interim analysis are reported, but since the efficacy boundaries were crossed, this report represents the final analysis.</div><div role="paragraph">Efficacy end points were assessed according to the intention-to-treat principle. Safety was assessed in all the patients who received at least one dose of avelumab in the avelumab group and in all the patients who completed the cycle 1, day 1, visit in the control group (safety population). Overall survival and progression-free survival were estimated by the Kaplan–Meier method. To account for the group-sequential design, two-sided repeated confidence intervals were constructed for the hazard ratio in the analysis of overall survival, and unadjusted 95% confidence intervals were also reported. Exact two-sided 95% confidence intervals for objective response according to treatment group were calculated by the Clopper–Pearson method. Stratified odds ratios for objective response were calculated by the Mantel–Haenszel method, which is analogous to logistic regression.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">Between May 11, 2016, and June 4, 2019, a total of 700 patients were enrolled at 197 sites in 29 countries. Patients were randomly assigned to receive best supportive care either with avelumab (avelumab group; 350 patients) or without avelumab (control group; 350 patients) (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). A total of 358 patients (51.1%) had PD-L1–positive tumors. The characteristics of the patients at baseline were balanced between the two treatment groups and between the overall population and the PD-L1–positive population (<a href="#t1">Table 1</a> and Table S1). Among patients with tumors that could be evaluated for PD-L1 status, tumors were PD-L1–positive in 189 of 328 patients (57.6%) in the avelumab group and in 169 of 300 patients (56.3%) in the control group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t1.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/8ce7a876-188a-4a5f-bbae-056156dfdd80/assets/images/large/nejmoa2002788_t1.jpg" height="1916" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Overall Population</span></th><th class="txxr-borders" colspan="2"><span>PD-L1–Positive Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Avelumab Group<br>(N=350)</th><th class="xxxx-borders">Control Group<br>(N=350)</th><th class="xxxx-borders">Avelumab Group<br>(N=189)</th><th class="xxxr-borders">Control Group<br>(N=169)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age — yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">68</td><td class="xxxx-borders">69</td><td class="xxxx-borders">70</td><td class="xxxr-borders">70</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">37–90</td><td class="xxxx-borders shading">32–89</td><td class="xxxx-borders shading">37–90</td><td class="xxxr-borders shading">32–84</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Site of primary tumor — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Upper tract</td><td class="xxxx-borders shading">106 (30.3)</td><td class="xxxx-borders shading">81 (23.1)</td><td class="xxxx-borders shading">44 (23.3)</td><td class="xxxr-borders shading">35 (20.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lower tract</td><td class="xxxx-borders">244 (69.7)</td><td class="xxxx-borders">269 (76.9)</td><td class="xxxx-borders">145 (76.7)</td><td class="xxxr-borders">134 (79.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Site of baseline metastasis before chemotherapy — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Visceral site</td><td class="xxxx-borders">191 (54.6)</td><td class="xxxx-borders">191 (54.6)</td><td class="xxxx-borders">88 (46.6)</td><td class="xxxr-borders">79 (46.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonvisceral site<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">159 (45.4)</td><td class="xxxx-borders shading">159 (45.4)</td><td class="xxxx-borders shading">101 (53.4)</td><td class="xxxr-borders shading">90 (53.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">PD-L1 status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Positive</td><td class="xxxx-borders shading">189 (54.0)</td><td class="xxxx-borders shading">169 (48.3)</td><td class="xxxx-borders shading">189 (100)</td><td class="xxxr-borders shading">169 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Negative</td><td class="xxxx-borders">139 (39.7)</td><td class="xxxx-borders">131 (37.4)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">22 (6.3)</td><td class="xxxx-borders shading">50 (14.3)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">First-line chemotherapy regimen — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Gemcitabine plus cisplatin</td><td class="xxxx-borders shading">183 (52.3)</td><td class="xxxx-borders shading">206 (58.9)</td><td class="xxxx-borders shading">101 (53.4)</td><td class="xxxr-borders shading">98 (58.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gemcitabine plus carboplatin</td><td class="xxxx-borders">147 (42.0)</td><td class="xxxx-borders">122 (34.9)</td><td class="xxxx-borders">74 (39.2)</td><td class="xxxr-borders">54 (32.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Gemcitabine plus cisplatin or carboplatin<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">20 (5.7)</td><td class="xxxx-borders shading">20 (5.7)</td><td class="xxxx-borders shading">14 (7.4)</td><td class="xxxr-borders shading">15 (8.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Not reported</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2 (1.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Best response to first-line chemotherapy — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response or partial response</td><td class="xxxx-borders">253 (72.3)</td><td class="xxxx-borders">252 (72.0)</td><td class="xxxx-borders">139 (73.5)</td><td class="xxxr-borders">128 (75.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Stable disease</td><td class="xbxx-borders shading">97 (27.7)</td><td class="xbxx-borders shading">98 (28.0)</td><td class="xbxx-borders shading">50 (26.5)</td><td class="xbxr-borders shading">41 (24.3)</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Positivity for programmed cell death ligand 1 (PD-L1) was defined as meeting one of the following criteria: expression in at least 25% of tumor cells, expression in at least 25% of tumor-associated immune cells if the percentage of immune cells was more than 1%, or expression in 100% of tumor-associated immune cells if the percentage of immune cells was no more than 1% (according to the SP263 assay). Patients in the avelumab group received avelumab and best supportive care, and patients in the control group received best supportive care alone. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The upper tract was defined as the renal pelvis or ureter, and the lower tract as the bladder, urethra, or prostate gland.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Patients with locally advanced disease were included in this category, in addition to those with only nonvisceral disease, including bone metastasis.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">This category includes patients who switched platinum-based regimens while receiving first-line chemotherapy.</div></div></div></figcaption></figure></div><div role="paragraph">At data cutoff on October 21, 2019, a total of 85 patients (24.3%) in the avelumab group and 26 patients (7.4%) in the control group were still receiving trial treatment. The most common reasons for permanent discontinuation of treatment were progressive disease (in 189 patients in the avelumab group [54.0%] and 263 in the control group [75.1%]), adverse events (in 39 [11.1%] and 2 [0.6%], respectively), withdrawal of consent (in 16 [4.6%] and 29 [8.3%]), and death (in 5 [1.4%] and 14 [4.0%]) (Fig. S1). In the overall population, a subsequent anticancer drug therapy was received by 148 patients (42.3%) in the avelumab group and by 216 patients (61.7%) in the control group, including an anti–PD-1 or anti–PD-L1 antibody in 22 patients (6.3%) in the avelumab group and in 153 patients (43.7%) in the control group (Table S2). The median follow-up for overall survival was more than 19 months in each treatment group.</div></section><section id="sec-2-2"><h3>Efficacy</h3><section id="sec-2-2-1"><h4>Primary End Point</h4><div role="paragraph">In the overall population, overall survival was significantly longer in the avelumab group than in the control group. Overall survival at 1 year (measured from randomization) was 71.3% (95% confidence interval [CI], 66.0 to 76.0) in the avelumab group, as compared with 58.4% (95% CI, 52.7 to 63.7) in the control group; the median overall survival was 21.4 months (95% CI, 18.9 to 26.1) and 14.3 months (95% CI, 12.9 to 17.9), respectively (stratified hazard ratio for death, 0.69; 95% CI, 0.56 to 0.86; repeated CI, 0.54 to 0.92; P=0.001) (<a href="#f1">Figure 1A</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f1.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/a2d2c49d-075d-4dc9-862c-b393d6f5dc20/assets/images/large/nejmoa2002788_f1.jpg" height="2771" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival in the Overall Population and the PD-L1–Positive Population.</div><div class="notes"><div role="doc-footnote">Patients in the avelumab group received avelumab and best supportive care, and patients in the control group received best supportive care alone. Tick marks indicate censored data. NE denotes could not be estimated, and PD-L1 programmed cell death ligand 1.</div></div></figcaption></figure></div><div role="paragraph">In the PD-L1–positive population, overall survival was also significantly longer in the avelumab group than in the control group. The overall survival at 1 year was 79.1% (95% CI, 72.1 to 84.5) in the avelumab group, as compared with 60.4% (95% CI, 52.0 to 67.7) in the control group (stratified hazard ratio, 0.56; 95% CI, 0.40 to 0.79; repeated CI, 0.39 to 0.94; P&lt;0.001) (<a href="#f1">Figure 1B</a>).</div><div role="paragraph">Overall survival in protocol-specified subgroups in the overall population is shown in Figure S2. Among patients with PD-L1–negative tumors, the median overall survival was 18.8 months (95% CI, 13.3 to 22.5) in the avelumab group and 13.7 months (95% CI, 10.8 to 17.8) in the control group (stratified hazard ratio for death, 0.85; 95% CI, 0.62 to 1.18) (Fig. S3A). In a stepwise multivariate Cox regression analysis that was performed in the overall population, the overall survival benefit with avelumab therapy as compared with control therapy, after adjustment for relevant baseline factors of potential prognostic effect, was consistent with the primary results (Table S3).</div></section><section id="sec-2-2-2"><h4>Secondary End Points</h4><div role="paragraph">Progression-free survival was longer in the avelumab group than in the control group in both primary populations. In the overall population, the median progression-free survival was 3.7 months (95% CI, 3.5 to 5.5) in the avelumab group and 2.0 months (95% CI, 1.9 to 2.7) in the control group (stratified hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75) (<a href="#f2">Figure 2A</a>). In the PD-L1–positive population, the median progression-free survival was 5.7 months (95% CI, 3.7 to 7.4) in the avelumab group and 2.1 months (95% CI, 1.9 to 3.5) in the control group (stratified hazard ratio, 0.56; 95% CI, 0.43 to 0.73) (<a href="#f2">Figure 2B</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f2.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/5e2f1004-896a-4924-9752-05e52da8baa5/assets/images/large/nejmoa2002788_f2.jpg" height="2772" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival in the Overall Population and the PD-L1–Positive Population.</div><div class="notes"><div role="doc-footnote">Progression was assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Tick marks indicate censored data.</div></div></figcaption></figure></div><div role="paragraph">Progression-free survival in protocol-specified subgroups is shown in Figure S4. In patients with PD-L1–negative tumors, the median progression-free survival was 3.0 months (95% CI, 2.0 to 3.7) in the avelumab group and 1.9 months (95% CI, 1.9 to 2.1) in the control group (stratified hazard ratio, 0.63; 95% CI, 0.47 to 0.85) (Fig. S3B). Response data are shown in <a href="#t2">Table 2</a>.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t2.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/6a4b688c-d226-4790-80ba-6c41c3bc2f20/assets/images/large/nejmoa2002788_t2.jpg" height="2145" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Overall Population</span></th><th class="txxr-borders" colspan="3"><span>PD-L1–Positive Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Avelumab<br>Group<br>(N=350)</th><th class="xxxx-borders">Control<br>Group<br>(N=350)</th><th class="xxxx-borders">Stratified<br>Odds Ratio<br>(95% CI)</th><th class="xxxx-borders">Avelumab<br>Group<br>(N=189)</th><th class="xxxx-borders">Control<br>Group<br>(N=169)</th><th class="xxxr-borders">Stratified<br>Odds Ratio<br>(95% CI)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confirmed objective response (95% CI) — %</td><td class="xxxx-borders shading">9.7<br>(6.8–13.3)</td><td class="xxxx-borders shading">1.4<br>(0.5–3.3)</td><td class="xxxx-borders shading">7.46<br>(2.82–24.45)</td><td class="xxxx-borders shading">13.8<br>(9.2–19.5)</td><td class="xxxx-borders shading">1.2<br>(0.1–4.2)</td><td class="xxxr-borders shading">12.70<br>(3.16–114.12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Confirmed best overall response — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Complete response</td><td class="xxxx-borders shading">21 (6.0)</td><td class="xxxx-borders shading">3 (0.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">18 (9.5)</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Partial response</td><td class="xxxx-borders">13 (3.7)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8 (4.2)</td><td class="xxxx-borders">1 (0.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Stable disease</td><td class="xxxx-borders shading">44 (12.6)</td><td class="xxxx-borders shading">46 (13.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">19 (10.1)</td><td class="xxxx-borders shading">23 (13.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Non–complete response or non–progressive disease<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">66 (18.9)</td><td class="xxxx-borders">45 (12.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">38 (20.1)</td><td class="xxxx-borders">22 (13.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive disease</td><td class="xxxx-borders shading">130 (37.1)</td><td class="xxxx-borders shading">169 (48.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">59 (31.2)</td><td class="xxxx-borders shading">82 (48.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Could not be evaluated</td><td class="xxxx-borders">76 (21.7)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">85 (24.3)<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">47 (24.9)<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">40 (23.7)<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Disease control — no. (%)<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">144 (41.1)</td><td class="xxxx-borders shading">96 (27.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">83 (43.9)</td><td class="xxxx-borders shading">47 (27.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Median time to objective response (range) — mo</td><td class="xbxx-borders">2.0<br>(1.7–16.4)</td><td class="xbxx-borders">2.0<br>(1.8–7.0)</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">2.0<br>(1.7–16.4)</td><td class="xbxx-borders">2.8<br>(1.8–3.8)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Responses in the Overall Population and the PD-L1–Positive Population.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">An objective response was defined as a complete or partial response. Objective responses were assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and indicated the change in tumors as compared with baseline at randomization (i.e., the change during chemotherapy was not considered). In patients with a complete response after chemotherapy, the best overall response was noted as “could not be evaluated” if no evidence of disease at baseline was detected after randomization or as “progressive disease” if disease progression occurred after randomization; these patients could not have had a best overall response of complete response, partial response, stable disease, or non–complete response or non–progressive disease after randomization. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">This category of response is defined by RECIST, version 1.1, and refers to persistence of one or more nontarget lesions in patients with nontarget lesions only.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 52 patients), no postbaseline assessments owing to other reasons (in 18), stable disease occurring less than 6 weeks after randomization (in 2), progressive disease occurring more than 12 weeks after randomization (in 2), no postbaseline assessments owing to early death (in 1), and new anticancer therapy started before the first postbaseline assessment (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 50 patients), no postbaseline assessments owing to other reasons (in 17), stable disease occurring less than 6 weeks after randomization (in 8), no postbaseline assessments owing to early death (in 4), new anticancer therapy started before the first postbaseline assessment (in 3), progressive disease occurring more than 12 weeks after randomization (in 2), and all postbaseline assessment had an overall response of “could not be evaluated” (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 31 patients), no postbaseline assessments owing to other reasons (in 12), stable disease occurring less than 6 weeks after randomization (in 1), no postbaseline assessments owing to early death (in 1), new anticancer therapy started before the first postbaseline assessment (in 1), and progressive disease occurring more than 12 weeks after randomization (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 28 patients), no postbaseline assessments owing to other reasons (in 5), stable disease occurring less than 6 weeks after randomization (in 3), progressive disease occurring more than 12 weeks after randomization (in 2), no postbaseline assessments owing to early death (in 1), and new anticancer therapy started before the first postbaseline assessment (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t2fn7" role="paragraph">Disease control was defined as a best overall response of complete response, partial response, stable disease, or non–complete response or non–progressive disease.</div></div></div></figcaption></figure></div></section></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph">Among all treated patients, the median duration of trial treatment was 24.9 weeks (range, 2.0 to 159.9) in the avelumab group and 13.1 weeks (range, 0.1 to 155.6) in the control group. Adverse events of any grade occurred in 337 of 344 patients (98.0%) in the avelumab group and in 268 of 345 patients (77.7%) in the control group, with adverse events of grade 3 or higher occurring in 163 patients (47.4%) and 87 patients (25.2%), respectively (<a href="#t3">Table 3</a> and Table S4). Serious adverse events are summarized in Table S5. In the avelumab group, adverse events led to treatment discontinuation in 41 patients (11.9%). Adverse events that were considered by the investigators to be related to treatment are listed in Table S6.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t3.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/e76a5764-ed03-473c-aa25-8246a3b74f8b/assets/images/large/nejmoa2002788_t3.jpg" height="1615" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-xml-align="left" data-type="row head1"><th class="txlx-borders">Event</th><th class="txxx-borders" data-xml-align="center" colspan="2"><span>Avelumab Group (N=344)</span></th><th class="txxr-borders" colspan="2"><span>Control Group (N=345)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade ≥3</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade ≥3</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">337 (98.0)</td><td class="xxxx-borders shading">163 (47.4)</td><td class="xxxx-borders shading">268 (77.7)</td><td class="xxxr-borders shading">87 (25.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">61 (17.7)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxx-borders">24 (7.0)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">59 (17.2)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">6 (1.7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders">59 (17.2)</td><td class="xxxx-borders">15 (4.4)</td><td class="xxxx-borders">36 (10.4)</td><td class="xxxr-borders">9 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">57 (16.6)</td><td class="xxxx-borders shading">2 (0.6)</td><td class="xxxx-borders shading">17 (4.9)</td><td class="xxxr-borders shading">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">56 (16.3)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">19 (5.5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">56 (16.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">19 (5.5)</td><td class="xxxr-borders shading">4 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">56 (16.3)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">31 (9.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Back pain</td><td class="xxxx-borders shading">55 (16.0)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">34 (9.9)</td><td class="xxxr-borders shading">8 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">54 (15.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">22 (6.4)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">51 (14.8)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">12 (3.5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">47 (13.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">23 (6.7)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cough</td><td class="xxxx-borders shading">44 (12.8)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">16 (4.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Vomiting</td><td class="xxxx-borders">43 (12.5)</td><td class="xxxx-borders">4 (1.2)</td><td class="xxxx-borders">12 (3.5)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypothyroidism</td><td class="xxxx-borders shading">40 (11.6)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">2 (0.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rash</td><td class="xxxx-borders">40 (11.6)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">4 (1.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">39 (11.3)</td><td class="xxxx-borders shading">13 (3.8)</td><td class="xxxx-borders shading">23 (6.7)</td><td class="xxxr-borders shading">10 (2.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hematuria</td><td class="xxxx-borders">36 (10.5)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxx-borders">37 (10.7)</td><td class="xxxr-borders">5 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Infusion-related reaction</td><td class="xbxx-borders shading">35 (10.2)</td><td class="xbxx-borders shading">3 (0.9)</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events (Safety Population).<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The safety population included all the patients in the avelumab group who received at least one dose of avelumab and all the patients in the control group who completed the cycle 1, day 1, visit. Shown are the adverse events of any grade and from any cause that occurred in at least 10% of these patients and the adverse events of grade 3 or higher and from any cause that occurred in at least 5% of these patients.</div></div></div></figcaption></figure></div><div role="paragraph">Death was attributed by the investigator to the toxicity of trial treatment in two patients (0.6%) in the avelumab group. One patient had sepsis after a urinary tract infection and possible central venous catheter infection after receiving 11 infusions of avelumab. The other patient had an ischemic stroke 100 days after receiving a single dose of avelumab and after disease progression and adverse events of limb venous thrombosis, pulmonary embolism, and acute myocardial infarction.</div><div role="paragraph"><a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">Among the avelumab-treated patients, 101 (29.4%) had an adverse event that was categorized as being immune-related according to a prespecified case definition, including 24 patients (7.0%) with a grade 3 event (Table S7). No grade 4 or fatal immune-related adverse events occurred. The most frequent category of immune-related adverse events was thyroid disorders, which occurred in 42 patients (12.2%). High-dose glucocorticoids (≥40 mg total daily dose of prednisone or equivalent) were administered after an immune-related adverse event in 31 patients (9.0%) who received avelumab.</span></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">This phase 3 trial showed that patients with advanced urothelial carcinoma who had disease that had not progressed with first-line platinum-based chemotherapy had significantly longer overall survival with maintenance avelumab therapy than with best supportive care alone; this finding applied to both the overall population and the PD-L1–positive population. Patients in the avelumab group also had longer progression-free survival than patients in the control group.</span> Overall survival was longer in the avelumab group despite the more frequent use of subsequent treatment in the control group (in 61.7% of patients), including immune checkpoint inhibitors (in 43.7%), a finding that highlights the benefit of starting avelumab immediately after first-line chemotherapy instead of waiting for disease progression. Furthermore, separation of the overall survival curves and the progression-free survival curves in favor of avelumab occurred early in the course of treatment and was maintained, which suggests that so-called hyperprogression (a potential and unexpected deleterious effect of treatment with a checkpoint inhibitor in which tumors would paradoxically progress faster than if they were untreated) did not occur with avelumab maintenance therapy in patients with advanced urothelial cancer. As expected, there was a higher incidence of adverse events in the avelumab group (active treatment) than in the control group (no active treatment), with adverse events of grade 3 or higher occurring in 47.4% and 25.2% of the patients, respectively. However, no new safety signals were identified, and 11.9% of the patients receiving maintenance avelumab discontinued the therapy because of adverse events.</div><div role="paragraph">The clinical usefulness of PD-L1 as a biomarker in advanced urothelial carcinoma is an area of uncertainty. PD-L1 expression in tumor or immune cells, detected by means of the Ventana SP142 and Agilent–Dako 22C3 assays, appears to be predictive of outcomes with first-line checkpoint inhibitor monotherapy for advanced urothelial carcinoma.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32 r33" id="body-ref-r33" href-manipulated="true">32,33</a></sup> PD-L1 expression appears to be prognostic in the context of second-line therapy.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r22" id="body-ref-r22-2" href-manipulated="true">15,22</a></sup> In this trial, we used the Ventana SP263 assay, which shows PD-L1 staining that is highly concordant with the Agilent–Dako 22C3 assay; however, because of their different manufacturer-specified algorithms, the SP263 assay classifies a higher proportion of samples as PD-L1–positive.<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34 r35 r36" id="body-ref-r36" href-manipulated="true">34-36</a></sup> In our trial, the overall survival benefit with avelumab as compared with control was somewhat greater in the PD-L1–positive population than in the overall population, but the result was significant in both populations. Furthermore, in the control group, the median overall survival was longer in the PD-L1–positive population (17.1 months) than in the overall population (14.3 months), a finding that suggests that PD-L1 expression may not be an indicator of worse prognosis in this population of patients who have disease control after chemotherapy. Further biomarker development in this context of the disease, including exploration of composite biomarker panels, may identify subgroups of patients with differences in clinical benefit.<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37 r38" id="body-ref-r38" href-manipulated="true">37,38</a></sup></div><div role="paragraph">Maintenance treatment with avelumab after chemotherapy is an extension of first-line treatment. The efficacy seen in the avelumab group may be due in part to maintenance treatment being administered only to patients with disease control; therefore, patients with rapidly progressive disease during first-line chemotherapy, which might be refractory to immunotherapy, were not included. However, these patients were not enrolled in either trial group, so no bias was introduced, and further studies to characterize patients with rapidly progressive (primary resistant) disease will be useful.</div><div role="paragraph">Several other phase 3 trials are exploring immune checkpoint inhibitors as first-line treatment for advanced urothelial carcinoma using different approaches (DANUBE [ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02516241" target="_blank">NCT02516241</a>]), KEYNOTE-361 [<a href="http://clinicaltrials.gov/show/NCT02853305" target="_blank">NCT02853305</a>], CheckMate901 [<a href="http://clinicaltrials.gov/show/NCT03036098" target="_blank">NCT03036098</a>], NILE [<a href="http://clinicaltrials.gov/show/NCT03682068" target="_blank">NCT03682068</a>], LEAP-011 [<a href="http://clinicaltrials.gov/show/NCT03898180" target="_blank">NCT03898180</a>], and EV-302 [<a href="http://clinicaltrials.gov/show/NCT04223856" target="_blank">NCT04223856</a>]).<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32-2" href-manipulated="true" aria-label="Reference 32">32</a></sup> Interim data have been reported from the IMvigor130 trial of first-line atezolizumab administered either concomitantly with platinum-based chemotherapy or as monotherapy, as compared with chemotherapy plus placebo, in patients with advanced disease.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32-3" href-manipulated="true" aria-label="Reference 32">32</a></sup> A final progression-free survival analysis showed a significant advantage with the combination therapy over placebo plus chemotherapy (median, 8.2 months vs. 6.3 months; hazard ratio for disease progression or death, 0.82; 95% CI, 0.70 to 0.96), whereas an interim overall survival analysis did not reach the prespecified threshold for significance (median, 16.0 months vs. 13.4 months; hazard ratio for death, 0.83; 95% CI, 0.69 to 1.00); the trial is ongoing until the final planned overall survival analysis. In both the JAVELIN Bladder 100 and IMvigor130 trials, immune checkpoint inhibitor treatment was continued until disease progression or until an unacceptable level of toxic effects occurred. In our trial, the overall survival benefit with avelumab maintenance therapy was similar in patients who had received first-line chemotherapy with cisplatin-based treatment and in those who had received carboplatin-based treatment. In the subgroup analysis of the IMvigor130 trial, overall survival appeared to be longer among patients who received atezolizumab plus cisplatin-based chemotherapy (median, 21.7 months, vs. 13.4 months in the placebo group; hazard ratio, 0.66; 95% CI, 0.47 to 0.94) than among those who received atezolizumab plus carboplatin-based chemotherapy (median, 14.2 months, vs. 13.4 months in the placebo group; hazard ratio, 0.91; 95% CI, 0.74 to 1.14).<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32-4" href-manipulated="true" aria-label="Reference 32">32</a></sup> Final results from this and other ongoing large, randomized trials in advanced urothelial carcinoma are awaited.</div><div role="paragraph">We found that first-line maintenance avelumab therapy in patients with advanced urothelial carcinoma with disease that had not progressed with platinum-based chemotherapy resulted in significantly longer overall survival than best supportive care alone.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on September 18, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Pfizer</span> as part of an alliance between <span class="named-content" data-type="funder">Pfizer</span> and <span class="named-content" data-type="funder">Merck</span> (Darmstadt, Germany).</div><div role="paragraph">Dr. Powles reports receiving grant support, paid to Bart’s Cancer Institute, and consulting fees from Astellas Pharma, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, Johnson &amp; Johnson Healthcare Systems, Merck Sharp &amp; Dohme, Novartis, and Seattle Genetics, grant support, paid to his institution, consulting fees, and travel support from AstraZeneca, grant support, paid to Bart’s Cancer Institute, consulting fees, and travel support from F. Hoffmann–La Roche, Ipsen Biopharmaceuticals, and Pfizer, and consulting fees from Incyte; Dr. Voog, receiving consulting fees from Novartis, Pfizer, and Sanofi; Dr. Caserta, receiving consulting fees from Janssen Biotech and Merck Sharp &amp; Dohme; Dr. Valderrama, receiving consulting fees and travel support from Astellas Pharma, Bristol-Myers Squibb, F. Hoffmann–La Roche, Ipsen Biopharmaceuticals, and Pfizer and consulting fees from Bayer Healthcare, EUSA Pharma, Merck Sharp &amp; Dohme, Novartis, Pierre Fabre Pharmaceuticals, and Sanofi; Dr. Gurney, receiving advisory board fees from AstraZeneca Australia, Bristol-Myers Squibb, F. Hoffmann–La Roche, Ipsen Biopharmaceuticals, Merck Sharp &amp; Dohme, and Pfizer; Dr. Kalofonos, receiving grant support and fees for serving as an expert witness from Amgen, Eli Lilly, EMD Serono, Genesis Pharma, Janssen Biotech, Merck Sharp &amp; Dohme, and Novartis, grant support from Bayer, travel support from Bristol-Myers Squibb, grant support, paid to the University of Patras, fees for serving as an expert witness, and travel support from F. Hoffmann–La Roche, fees for serving as an expert witness from LEO Pharma, and grant support, fees for serving as an expert witness, and travel support from Pfizer; Dr. Ullén, receiving consulting fees from Astellas Pharma; Dr. Loriot, receiving advisory board fees and travel support from Astellas Pharma, Bristol-Myers Squibb, Janssen Biotech, and Seattle Genetics, advisory board fees, lecture fees, and travel support from AstraZeneca and Merck Sharp &amp; Dohme, advisory board fees and lecture fees from Pfizer, and advisory board fees from Sanofi; Dr. Sridhar, receiving advisory board fees from AstraZeneca, Bristol-Myers Squibb, EMD Serono, F. Hoffmann–La Roche, and Merck Sharp &amp; Dohme and grant support, paid to Princess Margaret Cancer Centre, advisory board fees, and lecture fees from Pfizer; Dr. Tsuchiya, receiving lecture fees from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck Sharp &amp; Dohme, Novartis Pharma, Ono Pharma, Pfizer, Sanofi, and Takeda Pharmaceutical; Dr. Sternberg, receiving consulting fees from Astellas Pharma, AstraZeneca, Genentech, Incyte, Medscape Oncology, Merck (Darmstadt, Germany), Merck Sharp &amp; Dohme, Pfizer, Sanofi, Genzyme, and UroToday; Dr. Bellmunt, receiving advisory board fees and lecture fees from AstraZeneca and Merck Sharp &amp; Dohme, lecture fees from Bristol-Myers Squibb, advisory board fees from Genentech, Janssen Global Services, and Pierre Fabre Pharmaceuticals, advisory board fees and travel support from Pfizer, and grant support from Takeda Oncology; Dr. Aragon-Ching, receiving fees for serving on a speakers’ bureau from Astellas Pharma, Bristol-Myers Squibb, and Seattle Genetics and advisory board fees from EMD Serono; Dr. Petrylak, receiving grant support, paid to Yale University, and consulting fees from Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Pfizer, Roche Laboratories, and Seattle Genetics, consulting fees from Amgen, Boehringer Ingelheim, Exelixis, Incyte, Janssen, Pharmacyclics (an AbbVie Company), and UroGen Pharma, owning stock in Bellicum Pharmaceuticals, and grant support, paid to Yale University, from Endocyte, Genentech, Innocrin Pharma, MedImmune, Merck, Novartis, Progenics Pharmaceuticals, and Sanofi; Mr. Laliberte, being employed by and owning stock options in Pfizer; Dr. Wang, being employed by Pfizer; Drs. Huang, Davis, Fowst, and Costa, being employed by and owning stock in Pfizer; Dr. Blake-Haskins, being employed by and owning stock and stock options in Pfizer; Dr. di Pietro, being employed by and owning stock options in Pfizer; and Dr. Grivas, receiving grant support, paid to his institution, and receiving consulting fees from and participating in an educational program for Bristol-Myers Squibb, receiving grant support, paid to his institution, consulting fees, and travel support from AstraZeneca and Clovis Oncology, receiving grant support, paid to his institution, from Bavarian Nordic, Debiopharm, Immunomedics, and OncoGenex Pharmaceuticals, receiving grant support, paid to his institution, and consulting fees from Bayer, Genentech, GlaxoSmithKline, Merck, Mirati Therapeutics, Pfizer, and QED Therapeutics, and receiving consulting fees from Driver, EMD Serono, Exelixis, F. Hoffmann–La Roche, Foundation Medicine, Genzyme, Heron Therapeutics, Janssen, and Seattle Genetics. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and their families; the investigators, co-investigators, and trial teams at each of the centers; and Kelly Bryant, of ClinicalThinking, for medical writing assistance with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2002788_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002788/suppl_file/nejmoa2002788_protocol.pdf" download="nejmoa2002788_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002788_protocol.pdf" data-doi="10.1056/NEJMoa2002788">Download</a></li><li>4.33 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2002788_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002788/suppl_file/nejmoa2002788_appendix.pdf" download="nejmoa2002788_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002788_appendix.pdf" data-doi="10.1056/NEJMoa2002788">Download</a></li><li>1.51 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2002788_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002788/suppl_file/nejmoa2002788_disclosures.pdf" download="nejmoa2002788_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002788_disclosures.pdf" data-doi="10.1056/NEJMoa2002788">Download</a></li><li>1.21 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2002788_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002788/suppl_file/nejmoa2002788_data-sharing.pdf" download="nejmoa2002788_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002788_data-sharing.pdf" data-doi="10.1056/NEJMoa2002788">Download</a></li><li>73.61 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer, version 3. 2020 (<a href="https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf">https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=National+Comprehensive+Cancer+Network.+Clinical+practice+guidelines+in+oncology%3A+bladder+cancer%2C+version+3.+2020+%28https%3A%2F%2Fwww.nccn.org%2Fprofessionals%2Fphysician_gls%2FPDF%2Fbladder.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. <em>J Clin Oncol</em> 2000;18:3068-3077.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2000.18.17.3068" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11001674/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000089038300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gemcitabine+and+cisplatin+versus+methotrexate%2C+vinblastine%2C+doxorubicin%2C+and+cisplatin+in+advanced+or+metastatic+bladder+cancer%3A+results+of+a+large%2C+randomized%2C+multinational%2C+multicenter%2C+phase+III+study.&amp;publication_year=2000&amp;journal=J+Clin+Oncol&amp;pages=3068-3077&amp;doi=10.1200%2FJCO.2000.18.17.3068&amp;pmid=11001674" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. <em>J Clin Oncol</em> 2005;23:4602-4608.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2005.07.757" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16034041/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230872000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+survival+results+of+a+randomized+trial+comparing+gemcitabine+plus+cisplatin%2C+with+methotrexate%2C+vinblastine%2C+doxorubicin%2C+plus+cisplatin+in+patients+with+bladder+cancer.&amp;publication_year=2005&amp;journal=J+Clin+Oncol&amp;pages=4602-4608&amp;doi=10.1200%2FJCO.2005.07.757&amp;pmid=16034041" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Dogliotti L, Cartenì G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. <em>Eur Urol</em> 2007;52:134-141.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2006.12.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17207911/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000247281400023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gemcitabine+plus+cisplatin+versus+gemcitabine+plus+carboplatin+as+first-line+chemotherapy+in+advanced+transitional+cell+carcinoma+of+the+urothelium%3A+results+of+a+randomized+phase+2+trial.&amp;publication_year=2007&amp;journal=Eur+Urol&amp;pages=134-141&amp;doi=10.1016%2Fj.eururo.2006.12.029&amp;pmid=17207911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. <em>J Clin Oncol</em> 2012;30:191-199.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.37.3571" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22162575/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302619000021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+phase+II%2FIII+trial+assessing+gemcitabine%2Fcarboplatin+and+methotrexate%2Fcarboplatin%2Fvinblastine+in+patients+with+advanced+urothelial+cancer+who+are+unfit+for+cisplatin-based+chemotherapy%3A+EORTC+study+30986.&amp;publication_year=2012&amp;journal=J+Clin+Oncol&amp;pages=191-199&amp;doi=10.1200%2FJCO.2011.37.3571&amp;pmid=22162575" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. <em>ScientificWorldJournal</em> 2018;2018:5682078-5682078.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1155/2018/5682078" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29977169/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+the+treatment+of+metastatic+urothelial+carcinoma.&amp;publication_year=2018&amp;journal=ScientificWorldJournal&amp;pages=5682078-5682078&amp;doi=10.1155%2F2018%2F5682078&amp;pmid=29977169" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Grivas P, Monk BJ, Petrylak D, et al. Immune checkpoint inhibitors as switch or continuation maintenance therapy in solid tumors: rationale and current state. <em>Target Oncol</em> 2019;14:505-525.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11523-019-00665-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31535338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000490952700002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+checkpoint+inhibitors+as+switch+or+continuation+maintenance+therapy+in+solid+tumors%3A+rationale+and+current+state.&amp;publication_year=2019&amp;journal=Target+Oncol&amp;pages=505-525&amp;doi=10.1007%2Fs11523-019-00665-1&amp;pmid=31535338" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] has been shown to prolong overall survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] cross-resistance and cumulative toxicity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Grivas PD, Daignault S, Tagawa ST, et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <em>Cancer</em> 2014;120:692-701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.28477" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24249435/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000331454200010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Double-blind%2C+randomized%2C+phase+2+trial+of+maintenance+sunitinib+versus+placebo+after+response+to+chemotherapy+in+patients+with+advanced+urothelial+carcinoma.&amp;publication_year=2014&amp;journal=Cancer&amp;pages=692-701&amp;doi=10.1002%2Fcncr.28477&amp;pmid=24249435" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Powles T, Huddart RA, Elliott T, et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. <em>J Clin Oncol</em> 2017;35:48-55.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2015.66.3468" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28034079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391381300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+III%2C+double-blind%2C+randomized+trial+that+compared+maintenance+lapatinib+versus+placebo+after+first-line+chemotherapy+in+patients+with+human+epidermal+growth+factor+receptor+1%2F2-positive+metastatic+bladder+cancer.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=48-55&amp;doi=10.1200%2FJCO.2015.66.3468&amp;pmid=28034079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">García-Donas J, Font A, Pérez-Valderrama B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. <em>Lancet Oncol</em> 2017;18:672-681.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30242-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28389316/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400401100055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+therapy+with+vinflunine+plus+best+supportive+care+versus+best+supportive+care+alone+in+patients+with+advanced+urothelial+carcinoma+with+a+response+after+first-line+chemotherapy+%28MAJA%3B+SOGUG+2011%2F02%29%3A+a+multicentre%2C+randomised%2C+controlled%2C+open-label%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=672-681&amp;doi=10.1016%2FS1470-2045%2817%2930242-5&amp;pmid=28389316" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Rosenberg JE, Ballman KV, Halabi S, et al. CALGB 90601 (Alliance): randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. <em>J Clin Oncol</em> 2019;37:Suppl:4503-4503. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.15_suppl.4503" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000487345805330" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CALGB+90601+%28Alliance%29%3A+randomized%2C+double-blind%2C+placebo-controlled+phase+III+trial+comparing+gemcitabine+and+cisplatin+with+bevacizumab+or+placebo+in+patients+with+metastatic+urothelial+carcinoma.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=4503-4503&amp;doi=10.1200%2FJCO.2019.37.15_suppl.4503" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. <em>Curr Opin Oncol</em> 2015;27:191-200.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCO.0000000000000177" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25811346/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352650300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emerging+immunotherapies+for+bladder+cancer.&amp;publication_year=2015&amp;journal=Curr+Opin+Oncol&amp;pages=191-200&amp;doi=10.1097%2FCCO.0000000000000177&amp;pmid=25811346" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <em>Nature</em> 2018;554:544-548.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature25501" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29443960/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425597400050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TGF%CE%B2+attenuates+tumour+response+to+PD-L1+blockade+by+contributing+to+exclusion+of+T+cells.&amp;publication_year=2018&amp;journal=Nature&amp;pages=544-548&amp;doi=10.1038%2Fnature25501&amp;pmid=29443960" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Stenehjem DD, Tran D, Nkrumah MA, Gupta S. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. <em>Onco Targets Ther</em> 2018;11:5973-5989.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/OTT.S135157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30275703/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445039400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD1%2FPDL1+inhibitors+for+the+treatment+of+advanced+urothelial+bladder+cancer.&amp;publication_year=2018&amp;journal=Onco+Targets+Ther&amp;pages=5973-5989&amp;doi=10.2147%2FOTT.S135157&amp;pmid=30275703" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <em>Lancet</em> 2018;391:748-757.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)33297-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29268948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426054000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+chemotherapy+in+patients+with+platinum-treated+locally+advanced+or+metastatic+urothelial+carcinoma+%28IMvigor211%29%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=748-757&amp;doi=10.1016%2FS0140-6736%2817%2933297-X&amp;pmid=29268948" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the context of second-line therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <em>Lancet</em> 2016;387:1909-1920.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00561-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26952546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375374200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+in+patients+with+locally+advanced+and+metastatic+urothelial+carcinoma+who+have+progressed+following+treatment+with+platinum-based+chemotherapy%3A+a+single-arm%2C+multicentre%2C+phase+2+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1909-1920&amp;doi=10.1016%2FS0140-6736%2816%2900561-4&amp;pmid=26952546" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] among patients with PD-L1–negative tumors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <em>Lancet Oncol</em> 2018;19:51-64.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30900-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29217288/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419018200054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab+in+metastatic+urothelial+carcinoma+after+platinum+failure+%28JAVELIN+Solid+Tumor%29%3A+pooled+results+from+two+expansion+cohorts+of+an+open-label%2C+phase+1+trial.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=51-64&amp;doi=10.1016%2FS1470-2045%2817%2930900-2&amp;pmid=29217288" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the overall survival at 2 years was 20.1%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] among patients with PD-L1–negative tumors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. <em>J Clin Oncol</em> 2017;35:2117-2124.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.6795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28375787/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404378800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab%2C+an+anti%E2%80%93programmed+death-ligand+1+antibody%2C+in+patients+with+refractory+metastatic+urothelial+carcinoma%3A+results+from+a+multicenter%2C+phase+Ib+study.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=2117-2124&amp;doi=10.1200%2FJCO.2016.71.6795&amp;pmid=28375787" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] among patients with PD-L1–negative tumors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <em>Lancet Oncol</em> 2016;17:1590-1598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(16)30496-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27733243/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000389537600051" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+monotherapy+in+recurrent+metastatic+urothelial+carcinoma+%28CheckMate+032%29%3A+a+multicentre%2C+open-label%2C+two-stage%2C+multi-arm%2C+phase+1%2F2+trial.&amp;publication_year=2016&amp;journal=Lancet+Oncol&amp;pages=1590-1598&amp;doi=10.1016%2FS1470-2045%2816%2930496-X&amp;pmid=27733243" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <em>Lancet Oncol</em> 2017;18:312-322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30065-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28131785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396344600043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+in+metastatic+urothelial+carcinoma+after+platinum+therapy+%28CheckMate+275%29%3A+a+multicentre%2C+single-arm%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=312-322&amp;doi=10.1016%2FS1470-2045%2817%2930065-7&amp;pmid=28131785" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. <em>JAMA Oncol</em> 2017;3(9):e172411-e172411.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaoncol.2017.2411" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28817753/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410676400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+durvalumab+in+locally+advanced+or+metastatic+urothelial+carcinoma%3A+updated+results+from+a+phase+1%2F2+open-label+study.&amp;publication_year=2017&amp;journal=JAMA+Oncol&amp;pages=e172411-e172411&amp;doi=10.1001%2Fjamaoncol.2017.2411&amp;pmid=28817753" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] among patients with PD-L1–negative tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] tumors, would undergo randomization. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. <em>N Engl J Med</em> 2017;376:1015-1026.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002788&amp;key=10.1056%2FNEJMoa1613683&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28212060/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396403700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+as+second-line+therapy+for+advanced+urothelial+carcinoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1015-1026&amp;doi=10.1056%2FNEJMoa1613683&amp;pmid=28212060" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the context of second-line therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &gt;2 years of follow-up. <em>Ann Oncol</em> 2019;30:970-976.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz127" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31050707/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479284000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+phase+III+KEYNOTE-045+trial+of+pembrolizumab+versus+paclitaxel%2C+docetaxel%2C+or+vinflunine+in+recurrent+advanced+urothelial+cancer%3A+results+of+%3E2+years+of+follow-up.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=970-976&amp;doi=10.1093%2Fannonc%2Fmdz127&amp;pmid=31050707" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <em>Lancet Oncol</em> 2017;18:1483-1492.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30616-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28967485/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414134100055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+pembrolizumab+in+cisplatin-ineligible+patients+with+locally+advanced+and+unresectable+or+metastatic+urothelial+cancer+%28KEYNOTE-052%29%3A+a+multicentre%2C+single-arm%2C+phase+2+study.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=1483-1492&amp;doi=10.1016%2FS1470-2045%2817%2930616-2&amp;pmid=28967485" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <em>Lancet</em> 2017;389:67-76.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)32455-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27939400/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391264000039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+as+first-line+treatment+in+cisplatin-ineligible+patients+with+locally+advanced+and+metastatic+urothelial+carcinoma%3A+a+single-arm%2C+multicentre%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=67-76&amp;doi=10.1016%2FS0140-6736%2816%2932455-2&amp;pmid=27939400" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Gupta S, Sonpavde G, Grivas P, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). <em>J Clin Oncol</em> 2019;37:Suppl:451-451. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.7_suppl.451" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489108800467" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+%E2%80%9Cplatinum-ineligible%E2%80%9D+patients+with+metastatic+urothelial+cancer+%28mUC%29.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=451-451&amp;doi=10.1200%2FJCO.2019.37.7_suppl.451" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Szabados B, van Dijk N, Tang YZ, et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. <em>Eur Urol</em> 2018;73:149-152.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2017.08.022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28917596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419708200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+rate+to+chemotherapy+after+immune+checkpoint+inhibition+in+metastatic+urothelial+cancer.&amp;publication_year=2018&amp;journal=Eur+Urol&amp;pages=149-152&amp;doi=10.1016%2Fj.eururo.2017.08.022&amp;pmid=28917596" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Sonpavde GP, Mariani L, Lo Vullo S, et al. Impact of the number of cycles of platinum based first line chemotherapy for advanced urothelial carcinoma. <em>J Urol</em> 2018;200:1207-1214.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.juro.2018.07.035" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30012366/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449558500074" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+the+number+of+cycles+of+platinum+based+first+line+chemotherapy+for+advanced+urothelial+carcinoma.&amp;publication_year=2018&amp;journal=J+Urol&amp;pages=1207-1214&amp;doi=10.1016%2Fj.juro.2018.07.035&amp;pmid=30012366" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. <em>J Clin Oncol</em> 2020;38:1797-1806.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.03091" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32271672/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537770500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+double-blind+phase+II+study+of+maintenance+pembrolizumab+versus+placebo+after+first-line+chemotherapy+in+patients+with+metastatic+urothelial+cancer.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=1797-1806&amp;doi=10.1200%2FJCO.19.03091&amp;pmid=32271672" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Apolo AB, Ellerton JA, Infante JR, et al. Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: updated safety and efficacy analysis with ≥ two-years of follow-up. <em>J Clin Oncol</em> 2019;37:Suppl:425-425. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.7_suppl.425" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489108800441" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab+treatment+for+metastatic+urothelial+carcinoma+in+the+phase+Ib+JAVELIN+Solid+Tumor+Study%3A+updated+safety+and+efficacy+analysis+with+%E2%89%A5+two-years+of+follow-up.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=425-425&amp;doi=10.1200%2FJCO.2019.37.7_suppl.425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Zajac M, Boothman A-M, Ben Y, et al. Analytical validation and clinical utility of an immunohistochemical programmed death ligand-1 diagnostic assay and combined tumor and immune cell scoring algorithm for durvalumab in urothelial carcinoma. <em>Arch Pathol Lab Med</em> 2019;143:722-731.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5858/arpa.2017-0555-OA" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30457897/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000468925700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analytical+validation+and+clinical+utility+of+an+immunohistochemical+programmed+death+ligand-1+diagnostic+assay+and+combined+tumor+and+immune+cell+scoring+algorithm+for+durvalumab+in+urothelial+carcinoma.&amp;publication_year=2019&amp;journal=Arch+Pathol+Lab+Med&amp;pages=722-731&amp;doi=10.5858%2Farpa.2017-0555-OA&amp;pmid=30457897" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <em>Lancet</em> 2020;395:1547-1557.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r32" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30230-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536542900021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+with+or+without+chemotherapy+in+metastatic+urothelial+cancer+%28IMvigor130%29%3A+a+multicentre%2C+randomised%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1547-1557&amp;doi=10.1016%2FS0140-6736%2820%2930230-0&amp;pmid=32416780" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r32" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for advanced urothelial carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] NCT04223856]). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] placebo, in patients with advanced disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] hazard ratio, 0.91; 95% CI, 0.74 to 1.14). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. Press release of the Food and Drug Administration, updated August 16, 2018 (<a href="https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm">https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=FDA+alerts+health+care+professionals+and+oncology+clinical+investigators+about+an+efficacy+issue+identified+in+clinical+trials+for+some+patients+taking+Keytruda+%28pembrolizumab%29+or+Tecentriq+%28atezolizumab%29+as+monotherapy+to+treat+urothelial+cancer+with+low+expression+of+PD-L1.+Press+release+of+the+Food+and+Drug+Administration%2C+updated+August+16%2C+2018+%28https%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm608075.htm%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Schwamborn K, Ammann JU, Knüchel R, et al. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. <em>Virchows Arch</em> 2019;475:599-608.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00428-019-02610-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31267201/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000497269100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multicentric+analytical+comparability+study+of+programmed+death-ligand+1+expression+on+tumor-infiltrating+immune+cells+and+tumor+cells+in+urothelial+bladder+cancer+using+four+clinically+developed+immunohistochemistry+assays.&amp;publication_year=2019&amp;journal=Virchows+Arch&amp;pages=599-608&amp;doi=10.1007%2Fs00428-019-02610-z&amp;pmid=31267201" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Eckstein M, Erben P, Kriegmair MC, et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <em>Eur J Cancer</em> 2019;106:234-243.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2018.11.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30528808/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453243400026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Performance+of+the+Food+and+Drug+Administration%2FEMA-approved+programmed+cell+death+ligand-1+assays+in+urothelial+carcinoma+with+emphasis+on+therapy+stratification+for+first-line+use+of+atezolizumab+and+pembrolizumab.&amp;publication_year=2019&amp;journal=Eur+J+Cancer&amp;pages=234-243&amp;doi=10.1016%2Fj.ejca.2018.11.007&amp;pmid=30528808" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Zajac M, Scott M, Ratcliffe M, et al. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. <em>Diagn Pathol</em> 2019;14:99-99.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13000-019-0873-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31477145/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000483507600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Concordance+among+four+commercially+available%2C+validated+programmed+cell+death+ligand-1+assays+in+urothelial+carcinoma.&amp;publication_year=2019&amp;journal=Diagn+Pathol&amp;pages=99-99&amp;doi=10.1186%2Fs13000-019-0873-6&amp;pmid=31477145" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS. The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. <em>Eur Urol</em> 2019;75:435-444.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2018.09.022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30274701/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458490100031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+cancer+immunogram+as+a+framework+for+personalized+immunotherapy+in+urothelial+cancer.&amp;publication_year=2019&amp;journal=Eur+Urol&amp;pages=435-444&amp;doi=10.1016%2Fj.eururo.2018.09.022&amp;pmid=30274701" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <em>Ther Clin Risk Manag</em> 2018;14:1019-1040.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/TCRM.S158753" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29892196/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434035900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+checkpoint+inhibitors+in+urothelial+cancer%3A+recent+updates+and+future+outlook.&amp;publication_year=2018&amp;journal=Ther+Clin+Risk+Manag&amp;pages=1019-1040&amp;doi=10.2147%2FTCRM.S158753&amp;pmid=29892196" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/13"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">13</span></span> • <span property="datePublished">September 24, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1218</span>-<span property="pageEnd">1230</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: September 18, 2020</div><div><b class="core-label">Published in issue</b>: September 24, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/urology-prostate-disease-general" alt="View article keyword Urology/Prostate Disease General" data-interactiontype="article_recirculation_click">Urology/Prostate Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Thomas</span> <span property="familyName">Powles</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Se Hoon</span> <span property="familyName">Park</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eric</span> <span property="familyName">Voog</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Claudia</span> <span property="familyName">Caserta</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Begoña P.</span> <span property="familyName">Valderrama</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Howard</span> <span property="familyName">Gurney</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Haralabos</span> <span property="familyName">Kalofonos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Siniša</span> <span property="familyName">Radulović</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wim</span> <span property="familyName">Demey</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anders</span> <span property="familyName">Ullén</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yohann</span> <span property="familyName">Loriot</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Srikala S.</span> <span property="familyName">Sridhar</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Norihiko</span> <span property="familyName">Tsuchiya</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Evgeny</span> <span property="familyName">Kopyltsov</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cora N.</span> <span property="familyName">Sternberg</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joaquim</span> <span property="familyName">Bellmunt</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jeanny B.</span> <span property="familyName">Aragon-Ching</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daniel P.</span> <span property="familyName">Petrylak</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Laliberte</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jing</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bo</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Craig</span> <span property="familyName">Davis</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Camilla</span> <span property="familyName">Fowst</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nuno</span> <span property="familyName">Costa</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John A.</span> <span property="familyName">Blake-Haskins</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alessandra</span> <span property="familyName">di Pietro</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Petros</span> <span property="familyName">Grivas</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew’s Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) — both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) — both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology–Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) — both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) — both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Powles at Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew’s Hospital, Charterhouse Sq., London ECIM 6BQ, United Kingdom, or at <a href="mailto:thomas.powles1@nhs.net">thomas.powles1@nhs.net</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">1069</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2002788" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="dc6806f7-f490-c828-9b7a-3fcaf6679254"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665" style="display:inline-block;">
                <img alt="Article has an altmetric score of 526" src="https://badges.altmetric.com/?size=320&amp;score=526&amp;types=mabvctfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_dc6806f7-f490-c828-9b7a-3fcaf6679254" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=news">
          Picked up by <b>43</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=twitter">
          Posted by <b>307</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=90523665&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>661</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d64a8083a901a6-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2002788"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-13%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2002788%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="1069" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dimitra Rafailia Bakaloudi, </li><li class="list-inline-item cited-by__entry__author">Rafee Talukder, </li><li class="list-inline-item cited-by__entry__author">Thomas Enright, </li><li class="list-inline-item cited-by__entry__author">Jacob B. Leary, </li><li class="list-inline-item cited-by__entry__author">Dimitrios Makrakis, </li><li class="list-inline-item cited-by__entry__author">Leonidas N. Diamantopoulos, </li><li class="list-inline-item cited-by__entry__author">Charbel Hobeika, </li><li class="list-inline-item cited-by__entry__author">Vinay Mathew Thomas, </li><li class="list-inline-item cited-by__entry__author">Umang Swami, </li><li class="list-inline-item cited-by__entry__author">Roubini Zakopoulou, </li><li class="list-inline-item cited-by__entry__author">Aristotelis Bamias, </li><li class="list-inline-item cited-by__entry__author">Jason R. Brown, </li><li class="list-inline-item cited-by__entry__author">David J. Pinato, </li><li class="list-inline-item cited-by__entry__author">Charles Latchford, </li><li class="list-inline-item cited-by__entry__author">Tanya Jindal, </li><li class="list-inline-item cited-by__entry__author">Vadim S. Koshkin, </li><li class="list-inline-item cited-by__entry__author">Jure Murgić, </li><li class="list-inline-item cited-by__entry__author">Marija Miletić, </li><li class="list-inline-item cited-by__entry__author">Ana Frobe, </li><li class="list-inline-item cited-by__entry__author">Jeffrey Johnson, </li><li class="list-inline-item cited-by__entry__author">Yousef Zakharia, </li><li class="list-inline-item cited-by__entry__author">Ajjai Alva, </li><li class="list-inline-item cited-by__entry__author">Charles B. Nguyen, </li><li class="list-inline-item cited-by__entry__author">Gavin Hui, </li><li class="list-inline-item cited-by__entry__author">Alexandra Drakaki, </li><li class="list-inline-item cited-by__entry__author">Alejo Rodriguez-Vida, </li><li class="list-inline-item cited-by__entry__author">Macarena Rey-Cárdenas, </li><li class="list-inline-item cited-by__entry__author">Daniel Castellano, </li><li class="list-inline-item cited-by__entry__author">Lucia Alonso Buznego, </li><li class="list-inline-item cited-by__entry__author">Ignacio Duran, </li><li class="list-inline-item cited-by__entry__author">Rafael Morales Barrera, </li><li class="list-inline-item cited-by__entry__author">David Marmolejo, </li><li class="list-inline-item cited-by__entry__author">Rana R. McKay, </li><li class="list-inline-item cited-by__entry__author">Tyler F. Stewart, </li><li class="list-inline-item cited-by__entry__author">Pedro Barata, </li><li class="list-inline-item cited-by__entry__author">Ilana B. Epstein, </li><li class="list-inline-item cited-by__entry__author">Joaquim Bellmunt, </li><li class="list-inline-item cited-by__entry__author">Evan Y. Yu, </li><li class="list-inline-item cited-by__entry__author">Ruben Raychaudhuri, </li><li class="list-inline-item cited-by__entry__author">Rosa Nadal, </li><li class="list-inline-item cited-by__entry__author">Funda Vakar-Lopez, </li><li class="list-inline-item cited-by__entry__author">Shilpa Gupta, </li><li class="list-inline-item cited-by__entry__author">Jonathan L. Wright, </li><li class="list-inline-item cited-by__entry__author">Ali Raza Khaki, </li><li class="list-inline-item cited-by__entry__author">Petros Grivas, </li></ul><span class="cited-by__entry__title">Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes, </span><span class="cited-by__entry__series-title">Clinical Genitourinary Cancer, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(102356), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clgc.2025.102356" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clgc.2025.102356</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clgc.2025.102356" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yohei Okuda, </li><li class="list-inline-item cited-by__entry__author">Taigo Kato, </li><li class="list-inline-item cited-by__entry__author">Yu Ishizuya, </li><li class="list-inline-item cited-by__entry__author">Takuji Hayashi, </li><li class="list-inline-item cited-by__entry__author">Yoshiyuki Yamamoto, </li><li class="list-inline-item cited-by__entry__author">Koji Hatano, </li><li class="list-inline-item cited-by__entry__author">Atsunari Kawashima, </li><li class="list-inline-item cited-by__entry__author">Junko Murai, </li><li class="list-inline-item cited-by__entry__author">Norio Nonomura, </li></ul><span class="cited-by__entry__title">
                  PARP
              Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer
            , </span><span class="cited-by__entry__series-title">International Journal of Urology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/iju.70100" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/iju.70100</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/iju.70100" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Margitta Retz, </li><li class="list-inline-item cited-by__entry__author">Marc-Oliver Grimm, </li><li class="list-inline-item cited-by__entry__author">Katharina Leucht, </li><li class="list-inline-item cited-by__entry__author">Stefanie Zschäbitz, </li></ul><span class="cited-by__entry__title">Enfortumab Vedotin und PembrolizumabEnfortumab vedotin and pembrolizumab, </span><span class="cited-by__entry__series-title">best practice onkologie, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s11654-025-00663-y" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s11654-025-00663-y</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s11654-025-00663-y" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michael Cookson, </li><li class="list-inline-item cited-by__entry__author">Abhishek Tripathi, </li><li class="list-inline-item cited-by__entry__author">Sanjay Patel, </li><li class="list-inline-item cited-by__entry__author">Yan Daniel Zhao, </li><li class="list-inline-item cited-by__entry__author">Riza Fabreo, </li><li class="list-inline-item cited-by__entry__author">Andrew Cohoon, </li><li class="list-inline-item cited-by__entry__author">Viraj Maniar, </li><li class="list-inline-item cited-by__entry__author">Kelly Stratton, </li></ul><span class="cited-by__entry__title">A Phase 1b Study of Avelumab Plus Bacillus Calmette-Guérin in Patients With Nonmuscle-Invasive Bladder Cancer, </span><span class="cited-by__entry__series-title">JU Open Plus, </span><span class="cited-by__entry__volume"><strong>3</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/JU9.0000000000000296" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/JU9.0000000000000296</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/JU9.0000000000000296" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mahir Azmal, </li><li class="list-inline-item cited-by__entry__author">Md. Munna Miah, </li><li class="list-inline-item cited-by__entry__author">Fatema Sultana Prima, </li><li class="list-inline-item cited-by__entry__author">Jibon Kumar Paul, </li><li class="list-inline-item cited-by__entry__author">ANM Shah Newaz Been Haque, </li><li class="list-inline-item cited-by__entry__author">Ajit Ghosh, </li></ul><span class="cited-by__entry__title">Advances and challenges in cancer immunotherapy: Strategies for personalized treatment, </span><span class="cited-by__entry__series-title">Seminars in Oncology, </span><span class="cited-by__entry__volume"><strong>52</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(152345), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.seminoncol.2025.152345" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.seminoncol.2025.152345</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.seminoncol.2025.152345" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Joaquim Bellmunt, </li><li class="list-inline-item cited-by__entry__author">Thomas Powles, </li><li class="list-inline-item cited-by__entry__author">Se Hoon Park, </li><li class="list-inline-item cited-by__entry__author">Eric Voog, </li><li class="list-inline-item cited-by__entry__author">Begona P. Valderrama, </li><li class="list-inline-item cited-by__entry__author">Howard Gurney, </li><li class="list-inline-item cited-by__entry__author">Anders Ullén, </li><li class="list-inline-item cited-by__entry__author">Yohann Loriot, </li><li class="list-inline-item cited-by__entry__author">Srikala S. Sridhar, </li><li class="list-inline-item cited-by__entry__author">Norihiko Tsuchiya, </li><li class="list-inline-item cited-by__entry__author">Cora N. Sternberg, </li><li class="list-inline-item cited-by__entry__author">Jeanny B. Aragon-Ching, </li><li class="list-inline-item cited-by__entry__author">Daniel P. Petrylak, </li><li class="list-inline-item cited-by__entry__author">Miguel A. Climent Duran, </li><li class="list-inline-item cited-by__entry__author">Karin Tyroller, </li><li class="list-inline-item cited-by__entry__author">Jason Hoffman, </li><li class="list-inline-item cited-by__entry__author">Natalia Jacob, </li><li class="list-inline-item cited-by__entry__author">Petros Grivas, </li><li class="list-inline-item cited-by__entry__author">Shilpa Gupta, </li></ul><span class="cited-by__entry__title">Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease, </span><span class="cited-by__entry__series-title">European Urology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.eururo.2025.05.017" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.eururo.2025.05.017</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.eururo.2025.05.017" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alexandra Masson-Lecomte, </li><li class="list-inline-item cited-by__entry__author">Alison Birtle, </li><li class="list-inline-item cited-by__entry__author">Benjamin Pradere, </li><li class="list-inline-item cited-by__entry__author">Otakar Capoun, </li><li class="list-inline-item cited-by__entry__author">Eva Compérat, </li><li class="list-inline-item cited-by__entry__author">José L. Domínguez-Escrig, </li><li class="list-inline-item cited-by__entry__author">Fredrik Liedberg, </li><li class="list-inline-item cited-by__entry__author">Lydia Makaroff, </li><li class="list-inline-item cited-by__entry__author">Paramananthan Mariappan, </li><li class="list-inline-item cited-by__entry__author">Marco Moschini, </li><li class="list-inline-item cited-by__entry__author">Bhavan P. Rai, </li><li class="list-inline-item cited-by__entry__author">Bas W.G. van Rhijn, </li><li class="list-inline-item cited-by__entry__author">Shahrokh F. Shariat, </li><li class="list-inline-item cited-by__entry__author">Emma J. Smith, </li><li class="list-inline-item cited-by__entry__author">Jeremy Y.C. Teoh, </li><li class="list-inline-item cited-by__entry__author">Viktor Soukup, </li><li class="list-inline-item cited-by__entry__author">Robert Wood, </li><li class="list-inline-item cited-by__entry__author">Evanguelos N. Xylinas, </li><li class="list-inline-item cited-by__entry__author">Francesco Soria, </li><li class="list-inline-item cited-by__entry__author">Thomas Seisen, </li><li class="list-inline-item cited-by__entry__author">Paolo Gontero, </li></ul><span class="cited-by__entry__title">European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update, </span><span class="cited-by__entry__series-title">European Urology, </span><span class="cited-by__entry__volume"><strong>87</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(697-716), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.eururo.2025.02.023" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.eururo.2025.02.023</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.eururo.2025.02.023" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Bhavan Prasad Rai, </li><li class="list-inline-item cited-by__entry__author">Kalpesh Parmar, </li><li class="list-inline-item cited-by__entry__author">Benjamin Pradere, </li><li class="list-inline-item cited-by__entry__author">Otakar Capoun, </li><li class="list-inline-item cited-by__entry__author">Viktor Soukup, </li><li class="list-inline-item cited-by__entry__author">Paolo Gontero, </li><li class="list-inline-item cited-by__entry__author">Francesco Soria, </li><li class="list-inline-item cited-by__entry__author">Alison Birtle, </li><li class="list-inline-item cited-by__entry__author">Eva M. Compérat, </li><li class="list-inline-item cited-by__entry__author">Jose-Luis Dominguez-Escrig, </li><li class="list-inline-item cited-by__entry__author">Yuhong Yuan, </li><li class="list-inline-item cited-by__entry__author">Fredrik Liedberg, </li><li class="list-inline-item cited-by__entry__author">Hugh Mostafid, </li><li class="list-inline-item cited-by__entry__author">Morgan Rouprêt, </li><li class="list-inline-item cited-by__entry__author">Jeremy Y. Teoh, </li><li class="list-inline-item cited-by__entry__author">Marco Moschini, </li><li class="list-inline-item cited-by__entry__author">Paramananthan Mariappan, </li><li class="list-inline-item cited-by__entry__author">Bas W.G. van Rhijn, </li><li class="list-inline-item cited-by__entry__author">Shahrokh F. Shariat, </li><li class="list-inline-item cited-by__entry__author">Evanguelos Xylinas, </li><li class="list-inline-item cited-by__entry__author">Alexandra Masson-Lecomte, </li><li class="list-inline-item cited-by__entry__author">Thomas Seisen, </li></ul><span class="cited-by__entry__title">Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines, </span><span class="cited-by__entry__series-title">European Urology Oncology, </span><span class="cited-by__entry__volume"><strong>8</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(841-852), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.euo.2024.12.009" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.euo.2024.12.009</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.euo.2024.12.009" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">J. Hoffman-Censits, </li><li class="list-inline-item cited-by__entry__author">M. Tsiatas, </li><li class="list-inline-item cited-by__entry__author">P.M.-H. Chang, </li><li class="list-inline-item cited-by__entry__author">M. Kim, </li><li class="list-inline-item cited-by__entry__author">L. Antonuzzo, </li><li class="list-inline-item cited-by__entry__author">S.J. Shin, </li><li class="list-inline-item cited-by__entry__author">G. Gakis, </li><li class="list-inline-item cited-by__entry__author">N. Blais, </li><li class="list-inline-item cited-by__entry__author">S.H. Kim, </li><li class="list-inline-item cited-by__entry__author">A. Smith, </li><li class="list-inline-item cited-by__entry__author">J.A. Arranz Arija, </li><li class="list-inline-item cited-by__entry__author">Y.L. Su, </li><li class="list-inline-item cited-by__entry__author">F. Zagouri, </li><li class="list-inline-item cited-by__entry__author">M. Maruzzo, </li><li class="list-inline-item cited-by__entry__author">C. Tournigand, </li><li class="list-inline-item cited-by__entry__author">F. Forget, </li><li class="list-inline-item cited-by__entry__author">A. Schneider, </li><li class="list-inline-item cited-by__entry__author">K. Tyroller, </li><li class="list-inline-item cited-by__entry__author">N. Jacob, </li><li class="list-inline-item cited-by__entry__author">P. Grivas, </li><li class="list-inline-item cited-by__entry__author">B.P. Valderrama, </li></ul><span class="cited-by__entry__title">Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis, </span><span class="cited-by__entry__series-title">Annals of Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.annonc.2025.05.010" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.annonc.2025.05.010</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.annonc.2025.05.010" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kohei Shitara, </li><li class="list-inline-item cited-by__entry__author">Sylvie Lorenzen, </li><li class="list-inline-item cited-by__entry__author">Jin Li, </li><li class="list-inline-item cited-by__entry__author">Yuxian Bai, </li><li class="list-inline-item cited-by__entry__author">Manuel González Fernández, </li><li class="list-inline-item cited-by__entry__author">Mynor Aguilar, </li><li class="list-inline-item cited-by__entry__author">Hirokazu Shoji, </li><li class="list-inline-item cited-by__entry__author">Felipe Reyes-Cosmelli, </li><li class="list-inline-item cited-by__entry__author">Yovany Rodriguez Peña, </li><li class="list-inline-item cited-by__entry__author">Luis Corrales, </li><li class="list-inline-item cited-by__entry__author">Lucjan Wyrwicz, </li><li class="list-inline-item cited-by__entry__author">Daniel Acosta Eyzaguirre, </li><li class="list-inline-item cited-by__entry__author">Yueyin Pan, </li><li class="list-inline-item cited-by__entry__author">Min-Hee Ryu, </li><li class="list-inline-item cited-by__entry__author">Deirdre J. Cohen, </li><li class="list-inline-item cited-by__entry__author">Zev A. Wainberg, </li><li class="list-inline-item cited-by__entry__author">Geoffrey Ku, </li><li class="list-inline-item cited-by__entry__author">Josep Tabernero, </li><li class="list-inline-item cited-by__entry__author">Eric Van Cutsem, </li><li class="list-inline-item cited-by__entry__author">Shu-Kui Qin, </li><li class="list-inline-item cited-by__entry__author">Do-Youn Oh, </li><li class="list-inline-item cited-by__entry__author">Jianming Xu, </li><li class="list-inline-item cited-by__entry__author">Li Wen Liang, </li><li class="list-inline-item cited-by__entry__author">Sonal Bordia, </li><li class="list-inline-item cited-by__entry__author">Pooja Bhagia, </li><li class="list-inline-item cited-by__entry__author">Sun Young Rha, </li><li class="list-inline-item cited-by__entry__author">Ezequiel Heman Slutsky, </li><li class="list-inline-item cited-by__entry__author">Juan Cundom, </li><li class="list-inline-item cited-by__entry__author">Andrea Gabriela Soria, </li><li class="list-inline-item cited-by__entry__author">Marcela Alejandro Carballido, </li><li class="list-inline-item cited-by__entry__author">Juan Manuel O'Connor, </li><li class="list-inline-item cited-by__entry__author">Julieta Grasseli, </li><li class="list-inline-item cited-by__entry__author">Matthew Burge, </li><li class="list-inline-item cited-by__entry__author">Daniel Paul Brungs, </li><li class="list-inline-item cited-by__entry__author">Muhammad Adnan Khattak, </li><li class="list-inline-item cited-by__entry__author">Karen Paula Jozefa Geboes, </li><li class="list-inline-item cited-by__entry__author">Eric Van Cutsem, </li><li class="list-inline-item cited-by__entry__author">Jeroen Dekervel, </li><li class="list-inline-item cited-by__entry__author">Lionel D. Hondt, </li><li class="list-inline-item cited-by__entry__author">Frederic Lemay, </li><li class="list-inline-item cited-by__entry__author">Rosalyn Anne Juergens, </li><li class="list-inline-item cited-by__entry__author">Felipe Reyes, </li><li class="list-inline-item cited-by__entry__author">Gonzalo Pizarro Brito, </li><li class="list-inline-item cited-by__entry__author">Maria Alejandra Ojeda, </li><li class="list-inline-item cited-by__entry__author">Herman Adolfo Araya, </li><li class="list-inline-item cited-by__entry__author">Patricio Eduardo Yanez, </li><li class="list-inline-item cited-by__entry__author">Jianwei Yang, </li><li class="list-inline-item cited-by__entry__author">Xi Chen, </li><li class="list-inline-item cited-by__entry__author">Yuxian Bai, </li><li class="list-inline-item cited-by__entry__author">Hongming Pan, </li><li class="list-inline-item cited-by__entry__author">Nong Xu, </li><li class="list-inline-item cited-by__entry__author">Yueyin Pan, </li><li class="list-inline-item cited-by__entry__author">Qinghong Guo, </li><li class="list-inline-item cited-by__entry__author">Baorui Liu, </li><li class="list-inline-item cited-by__entry__author">Feng Ye, </li><li class="list-inline-item cited-by__entry__author">Xin Wang, </li><li class="list-inline-item cited-by__entry__author">Qi Li, </li><li class="list-inline-item cited-by__entry__author">Yong Tang, </li><li class="list-inline-item cited-by__entry__author">Huiting Xu, </li><li class="list-inline-item cited-by__entry__author">Haichuan Su, </li><li class="list-inline-item cited-by__entry__author">Ying Cheng, </li><li class="list-inline-item cited-by__entry__author">Xianli Yin, </li><li class="list-inline-item cited-by__entry__author">Qun Zhao, </li><li class="list-inline-item cited-by__entry__author">Ning Li, </li><li class="list-inline-item cited-by__entry__author">Jun You, </li><li class="list-inline-item cited-by__entry__author">Yi Ba, </li><li class="list-inline-item cited-by__entry__author">Jinsheng We, </li><li class="list-inline-item cited-by__entry__author">Lin Shen, </li><li class="list-inline-item cited-by__entry__author">Jin Li, </li><li class="list-inline-item cited-by__entry__author">Wangjun Liao, </li><li class="list-inline-item cited-by__entry__author">Zhen Li, </li><li class="list-inline-item cited-by__entry__author">Lei Yang, </li><li class="list-inline-item cited-by__entry__author">Yovany Eduardo Rodriguez Pena, </li><li class="list-inline-item cited-by__entry__author">Ivan Jose Bustillo, </li><li class="list-inline-item cited-by__entry__author">Carlos Jose Narvaez, </li><li class="list-inline-item cited-by__entry__author">Manuel Enrique Gonzalez Fernandez, </li><li class="list-inline-item cited-by__entry__author">Raimundo Manneh, </li><li class="list-inline-item cited-by__entry__author">Andres Fernando Arenas Arias, </li><li class="list-inline-item cited-by__entry__author">Luis Corrales, </li><li class="list-inline-item cited-by__entry__author">Andres Wiernik Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Thomas Aparicio, </li><li class="list-inline-item cited-by__entry__author">Yuan Touchefeu, </li><li class="list-inline-item cited-by__entry__author">Helene Boussion-Desloges, </li><li class="list-inline-item cited-by__entry__author">Laurent Mineur, </li><li class="list-inline-item cited-by__entry__author">Christophe Tournigand, </li><li class="list-inline-item cited-by__entry__author">Francois Ghiringhelli, </li><li class="list-inline-item cited-by__entry__author">Marie Pierre Galais, </li><li class="list-inline-item cited-by__entry__author">Eric Terrebonne, </li><li class="list-inline-item cited-by__entry__author">Thomas Walter, </li><li class="list-inline-item cited-by__entry__author">Mathieu Baconnier, </li><li class="list-inline-item cited-by__entry__author">Sylvie Lorenzen, </li><li class="list-inline-item cited-by__entry__author">Eray Goekkurt, </li><li class="list-inline-item cited-by__entry__author">Annika Kurreck, </li><li class="list-inline-item cited-by__entry__author">Arne Kandulski, </li><li class="list-inline-item cited-by__entry__author">Thorsten Goetze, </li><li class="list-inline-item cited-by__entry__author">Florian Lordick, </li><li class="list-inline-item cited-by__entry__author">Mynor Aguilar, </li><li class="list-inline-item cited-by__entry__author">Karla Alejandra Lopez, </li><li class="list-inline-item cited-by__entry__author">Rixci Augusto Lenin Ramirez Fallas, </li><li class="list-inline-item cited-by__entry__author">Pier Anyelo Ramos Elias, </li><li class="list-inline-item cited-by__entry__author">Juan Pablo Moreira, </li><li class="list-inline-item cited-by__entry__author">Wing Lok Wendy Chan, </li><li class="list-inline-item cited-by__entry__author">Ashely Cheng, </li><li class="list-inline-item cited-by__entry__author">Winnie Yeo, </li><li class="list-inline-item cited-by__entry__author">Maeve Lowery, </li><li class="list-inline-item cited-by__entry__author">Adrian Murphy, </li><li class="list-inline-item cited-by__entry__author">Sharon Pelles Avraham, </li><li class="list-inline-item cited-by__entry__author">Ayala Hubert, </li><li class="list-inline-item cited-by__entry__author">Irit Ben-Aharon, </li><li class="list-inline-item cited-by__entry__author">Valeriya Semenisty, </li><li class="list-inline-item cited-by__entry__author">Gali Perl, </li><li class="list-inline-item cited-by__entry__author">Wael Hozaeel, </li><li class="list-inline-item cited-by__entry__author">Armando Santoro, </li><li class="list-inline-item cited-by__entry__author">Elena Aurelia Mazza, </li><li class="list-inline-item cited-by__entry__author">Ferdinando de Vita, </li><li class="list-inline-item cited-by__entry__author">Guiseppe Aprile, </li><li class="list-inline-item cited-by__entry__author">Giovanni Gerardo Cardellino, </li><li class="list-inline-item cited-by__entry__author">Filippo Pietrantonio, </li><li class="list-inline-item cited-by__entry__author">Pierfrancesco Tassone, </li><li class="list-inline-item cited-by__entry__author">Kohei Shitara, </li><li class="list-inline-item cited-by__entry__author">Hirokazu Shoji, </li><li class="list-inline-item cited-by__entry__author">Yukiya Narita, </li><li class="list-inline-item cited-by__entry__author">Hiroki Hara, </li><li class="list-inline-item cited-by__entry__author">Kensei Yamaguchi, </li><li class="list-inline-item cited-by__entry__author">Naotoshi Sugimoto, </li><li class="list-inline-item cited-by__entry__author">Nozomu Machida, </li><li class="list-inline-item cited-by__entry__author">Tomohiro Nishina, </li><li class="list-inline-item cited-by__entry__author">Akihito Tsuji, </li><li class="list-inline-item cited-by__entry__author">Yasuhiro Choda, </li><li class="list-inline-item cited-by__entry__author">Kenji Amagai, </li><li class="list-inline-item cited-by__entry__author">Masahiro Tsuda, </li><li class="list-inline-item cited-by__entry__author">Shogen Boku, </li><li class="list-inline-item cited-by__entry__author">Boguslawa Karaszewska, </li><li class="list-inline-item cited-by__entry__author">Kamil Stanislaw Kuc, </li><li class="list-inline-item cited-by__entry__author">Jacek Mackiewicz, </li><li class="list-inline-item cited-by__entry__author">Lucjan Stanislaw Wyrwicz, </li><li class="list-inline-item cited-by__entry__author">Lukasz Hajac, </li><li class="list-inline-item cited-by__entry__author">Alexy Alexandrovich Tryakin, </li><li class="list-inline-item cited-by__entry__author">Dmitry Aleksandrovich Nosov, </li><li class="list-inline-item cited-by__entry__author">Rashida Orlova, </li><li class="list-inline-item cited-by__entry__author">Alexey Mikhailovich Karachun, </li><li class="list-inline-item cited-by__entry__author">Michael Osipov, </li><li class="list-inline-item cited-by__entry__author">Mikhail Valerievich Kopp, </li><li class="list-inline-item cited-by__entry__author">Natalia Vladimirovna Fadeeva, </li><li class="list-inline-item cited-by__entry__author">Nikolay Viktorovich Kislov, </li><li class="list-inline-item cited-by__entry__author">Sun Young Rha, </li><li class="list-inline-item cited-by__entry__author">Seung Tae Kim, </li><li class="list-inline-item cited-by__entry__author">Min-Hee Ryu, </li><li class="list-inline-item cited-by__entry__author">Do-Youn Oh, </li><li class="list-inline-item cited-by__entry__author">Keun-Wook Lee, </li><li class="list-inline-item cited-by__entry__author">Hei-Cheul Jeung, </li><li class="list-inline-item cited-by__entry__author">Jonggwon Choi, </li><li class="list-inline-item cited-by__entry__author">Sang Cheul Oh, </li><li class="list-inline-item cited-by__entry__author">Paula Jimenez Fonseca, </li><li class="list-inline-item cited-by__entry__author">Fernando Rivera Herrero, </li><li class="list-inline-item cited-by__entry__author">Pilar Aitana Calvo Ferrandiz, </li><li class="list-inline-item cited-by__entry__author">Daniel Acosta Eyzaguirre, </li><li class="list-inline-item cited-by__entry__author">Kun-Huei Yeh, </li><li class="list-inline-item cited-by__entry__author">Jen-Shi Chen, </li><li class="list-inline-item cited-by__entry__author">Li-Yuan Bai, </li><li class="list-inline-item cited-by__entry__author">Chia-Jui Yen, </li><li class="list-inline-item cited-by__entry__author">Bulent Erdogan, </li><li class="list-inline-item cited-by__entry__author">Pinar Gursoy, </li><li class="list-inline-item cited-by__entry__author">Mustafa Ozguroglu, </li><li class="list-inline-item cited-by__entry__author">Suayib Yalcin, </li><li class="list-inline-item cited-by__entry__author">Umut Demirci, </li><li class="list-inline-item cited-by__entry__author">Mehmet Bilici, </li><li class="list-inline-item cited-by__entry__author">Ilhan Hacibekiroglu, </li><li class="list-inline-item cited-by__entry__author">Hugo Ford, </li><li class="list-inline-item cited-by__entry__author">Kai-Keen Shiu, </li><li class="list-inline-item cited-by__entry__author">Martin Scott-Brown, </li><li class="list-inline-item cited-by__entry__author">Russell Petty, </li><li class="list-inline-item cited-by__entry__author">Wasat Mansoor, </li><li class="list-inline-item cited-by__entry__author">Zev A. Wainberg, </li><li class="list-inline-item cited-by__entry__author">Marcus Noel, </li><li class="list-inline-item cited-by__entry__author">Peter Enzinger, </li><li class="list-inline-item cited-by__entry__author">Sreenivasa Chandana, </li><li class="list-inline-item cited-by__entry__author">Geoffrey Ku, </li><li class="list-inline-item cited-by__entry__author">Dierdre Cohen, </li><li class="list-inline-item cited-by__entry__author">Vincent Lam, </li></ul><span class="cited-by__entry__title">Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study, </span><span class="cited-by__entry__series-title">Journal of Clinical Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/JCO-25-00748" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/JCO-25-00748</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/JCO-25-00748" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-13%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2002788%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2002788" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2002788" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2002788.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f1.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/a2d2c49d-075d-4dc9-862c-b393d6f5dc20/assets/images/large/nejmoa2002788_f1.jpg" height="2771" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival in the Overall Population and the PD-L1–Positive Population.</div><div class="notes"><div role="doc-footnote">Patients in the avelumab group received avelumab and best supportive care, and patients in the control group received best supportive care alone. Tick marks indicate censored data. NE denotes could not be estimated, and PD-L1 programmed cell death ligand 1.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f2.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/5e2f1004-896a-4924-9752-05e52da8baa5/assets/images/large/nejmoa2002788_f2.jpg" height="2772" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival in the Overall Population and the PD-L1–Positive Population.</div><div class="notes"><div role="doc-footnote">Progression was assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Tick marks indicate censored data.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2002788/asset/8ce7a876-188a-4a5f-bbae-056156dfdd80/assets/images/large/nejmoa2002788_t1.jpg" height="1916" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Overall Population</span></th><th class="txxr-borders" colspan="2"><span>PD-L1–Positive Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Avelumab Group<br>(N=350)</th><th class="xxxx-borders">Control Group<br>(N=350)</th><th class="xxxx-borders">Avelumab Group<br>(N=189)</th><th class="xxxr-borders">Control Group<br>(N=169)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age — yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">68</td><td class="xxxx-borders">69</td><td class="xxxx-borders">70</td><td class="xxxr-borders">70</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">37–90</td><td class="xxxx-borders shading">32–89</td><td class="xxxx-borders shading">37–90</td><td class="xxxr-borders shading">32–84</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Site of primary tumor — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Upper tract</td><td class="xxxx-borders shading">106 (30.3)</td><td class="xxxx-borders shading">81 (23.1)</td><td class="xxxx-borders shading">44 (23.3)</td><td class="xxxr-borders shading">35 (20.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lower tract</td><td class="xxxx-borders">244 (69.7)</td><td class="xxxx-borders">269 (76.9)</td><td class="xxxx-borders">145 (76.7)</td><td class="xxxr-borders">134 (79.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Site of baseline metastasis before chemotherapy — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Visceral site</td><td class="xxxx-borders">191 (54.6)</td><td class="xxxx-borders">191 (54.6)</td><td class="xxxx-borders">88 (46.6)</td><td class="xxxr-borders">79 (46.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonvisceral site<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">159 (45.4)</td><td class="xxxx-borders shading">159 (45.4)</td><td class="xxxx-borders shading">101 (53.4)</td><td class="xxxr-borders shading">90 (53.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">PD-L1 status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Positive</td><td class="xxxx-borders shading">189 (54.0)</td><td class="xxxx-borders shading">169 (48.3)</td><td class="xxxx-borders shading">189 (100)</td><td class="xxxr-borders shading">169 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Negative</td><td class="xxxx-borders">139 (39.7)</td><td class="xxxx-borders">131 (37.4)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">22 (6.3)</td><td class="xxxx-borders shading">50 (14.3)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">First-line chemotherapy regimen — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Gemcitabine plus cisplatin</td><td class="xxxx-borders shading">183 (52.3)</td><td class="xxxx-borders shading">206 (58.9)</td><td class="xxxx-borders shading">101 (53.4)</td><td class="xxxr-borders shading">98 (58.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gemcitabine plus carboplatin</td><td class="xxxx-borders">147 (42.0)</td><td class="xxxx-borders">122 (34.9)</td><td class="xxxx-borders">74 (39.2)</td><td class="xxxr-borders">54 (32.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Gemcitabine plus cisplatin or carboplatin<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">20 (5.7)</td><td class="xxxx-borders shading">20 (5.7)</td><td class="xxxx-borders shading">14 (7.4)</td><td class="xxxr-borders shading">15 (8.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Not reported</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2 (1.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Best response to first-line chemotherapy — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response or partial response</td><td class="xxxx-borders">253 (72.3)</td><td class="xxxx-borders">252 (72.0)</td><td class="xxxx-borders">139 (73.5)</td><td class="xxxr-borders">128 (75.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Stable disease</td><td class="xbxx-borders shading">97 (27.7)</td><td class="xbxx-borders shading">98 (28.0)</td><td class="xbxx-borders shading">50 (26.5)</td><td class="xbxr-borders shading">41 (24.3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Positivity for programmed cell death ligand 1 (PD-L1) was defined as meeting one of the following criteria: expression in at least 25% of tumor cells, expression in at least 25% of tumor-associated immune cells if the percentage of immune cells was more than 1%, or expression in 100% of tumor-associated immune cells if the percentage of immune cells was no more than 1% (according to the SP263 assay). Patients in the avelumab group received avelumab and best supportive care, and patients in the control group received best supportive care alone. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The upper tract was defined as the renal pelvis or ureter, and the lower tract as the bladder, urethra, or prostate gland.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Patients with locally advanced disease were included in this category, in addition to those with only nonvisceral disease, including bone metastasis.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">This category includes patients who switched platinum-based regimens while receiving first-line chemotherapy.</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2002788/asset/6a4b688c-d226-4790-80ba-6c41c3bc2f20/assets/images/large/nejmoa2002788_t2.jpg" height="2145" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Overall Population</span></th><th class="txxr-borders" colspan="3"><span>PD-L1–Positive Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Avelumab<br>Group<br>(N=350)</th><th class="xxxx-borders">Control<br>Group<br>(N=350)</th><th class="xxxx-borders">Stratified<br>Odds Ratio<br>(95% CI)</th><th class="xxxx-borders">Avelumab<br>Group<br>(N=189)</th><th class="xxxx-borders">Control<br>Group<br>(N=169)</th><th class="xxxr-borders">Stratified<br>Odds Ratio<br>(95% CI)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confirmed objective response (95% CI) — %</td><td class="xxxx-borders shading">9.7<br>(6.8–13.3)</td><td class="xxxx-borders shading">1.4<br>(0.5–3.3)</td><td class="xxxx-borders shading">7.46<br>(2.82–24.45)</td><td class="xxxx-borders shading">13.8<br>(9.2–19.5)</td><td class="xxxx-borders shading">1.2<br>(0.1–4.2)</td><td class="xxxr-borders shading">12.70<br>(3.16–114.12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Confirmed best overall response — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Complete response</td><td class="xxxx-borders shading">21 (6.0)</td><td class="xxxx-borders shading">3 (0.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">18 (9.5)</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Partial response</td><td class="xxxx-borders">13 (3.7)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8 (4.2)</td><td class="xxxx-borders">1 (0.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Stable disease</td><td class="xxxx-borders shading">44 (12.6)</td><td class="xxxx-borders shading">46 (13.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">19 (10.1)</td><td class="xxxx-borders shading">23 (13.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Non–complete response or non–progressive disease<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">66 (18.9)</td><td class="xxxx-borders">45 (12.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">38 (20.1)</td><td class="xxxx-borders">22 (13.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive disease</td><td class="xxxx-borders shading">130 (37.1)</td><td class="xxxx-borders shading">169 (48.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">59 (31.2)</td><td class="xxxx-borders shading">82 (48.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Could not be evaluated</td><td class="xxxx-borders">76 (21.7)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">85 (24.3)<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">47 (24.9)<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">40 (23.7)<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Disease control — no. (%)<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">144 (41.1)</td><td class="xxxx-borders shading">96 (27.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">83 (43.9)</td><td class="xxxx-borders shading">47 (27.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Median time to objective response (range) — mo</td><td class="xbxx-borders">2.0<br>(1.7–16.4)</td><td class="xbxx-borders">2.0<br>(1.8–7.0)</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">2.0<br>(1.7–16.4)</td><td class="xbxx-borders">2.8<br>(1.8–3.8)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">An objective response was defined as a complete or partial response. Objective responses were assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and indicated the change in tumors as compared with baseline at randomization (i.e., the change during chemotherapy was not considered). In patients with a complete response after chemotherapy, the best overall response was noted as “could not be evaluated” if no evidence of disease at baseline was detected after randomization or as “progressive disease” if disease progression occurred after randomization; these patients could not have had a best overall response of complete response, partial response, stable disease, or non–complete response or non–progressive disease after randomization. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">This category of response is defined by RECIST, version 1.1, and refers to persistence of one or more nontarget lesions in patients with nontarget lesions only.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 52 patients), no postbaseline assessments owing to other reasons (in 18), stable disease occurring less than 6 weeks after randomization (in 2), progressive disease occurring more than 12 weeks after randomization (in 2), no postbaseline assessments owing to early death (in 1), and new anticancer therapy started before the first postbaseline assessment (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 50 patients), no postbaseline assessments owing to other reasons (in 17), stable disease occurring less than 6 weeks after randomization (in 8), no postbaseline assessments owing to early death (in 4), new anticancer therapy started before the first postbaseline assessment (in 3), progressive disease occurring more than 12 weeks after randomization (in 2), and all postbaseline assessment had an overall response of “could not be evaluated” (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 31 patients), no postbaseline assessments owing to other reasons (in 12), stable disease occurring less than 6 weeks after randomization (in 1), no postbaseline assessments owing to early death (in 1), new anticancer therapy started before the first postbaseline assessment (in 1), and progressive disease occurring more than 12 weeks after randomization (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">Reasons that the response could not be evaluated were the following: no evidence of disease at baseline (in 28 patients), no postbaseline assessments owing to other reasons (in 5), stable disease occurring less than 6 weeks after randomization (in 3), progressive disease occurring more than 12 weeks after randomization (in 2), no postbaseline assessments owing to early death (in 1), and new anticancer therapy started before the first postbaseline assessment (in 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t2fn7" role="paragraph" data-to-manipulate="true">Disease control was defined as a best overall response of complete response, partial response, stable disease, or non–complete response or non–progressive disease.</div></div></div></figcaption></a><figcaption><div class="caption">Responses in the Overall Population and the PD-L1–Positive Population.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2002788/asset/e76a5764-ed03-473c-aa25-8246a3b74f8b/assets/images/large/nejmoa2002788_t3.jpg" height="1615" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-xml-align="left" data-type="row head1"><th class="txlx-borders">Event</th><th class="txxx-borders" data-xml-align="center" colspan="2"><span>Avelumab Group (N=344)</span></th><th class="txxr-borders" colspan="2"><span>Control Group (N=345)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade ≥3</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade ≥3</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">337 (98.0)</td><td class="xxxx-borders shading">163 (47.4)</td><td class="xxxx-borders shading">268 (77.7)</td><td class="xxxr-borders shading">87 (25.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">61 (17.7)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxx-borders">24 (7.0)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">59 (17.2)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">6 (1.7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders">59 (17.2)</td><td class="xxxx-borders">15 (4.4)</td><td class="xxxx-borders">36 (10.4)</td><td class="xxxr-borders">9 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">57 (16.6)</td><td class="xxxx-borders shading">2 (0.6)</td><td class="xxxx-borders shading">17 (4.9)</td><td class="xxxr-borders shading">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">56 (16.3)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">19 (5.5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">56 (16.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">19 (5.5)</td><td class="xxxr-borders shading">4 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">56 (16.3)</td><td class="xxxx-borders">2 (0.6)</td><td class="xxxx-borders">31 (9.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Back pain</td><td class="xxxx-borders shading">55 (16.0)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">34 (9.9)</td><td class="xxxr-borders shading">8 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">54 (15.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">22 (6.4)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">51 (14.8)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">12 (3.5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">47 (13.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">23 (6.7)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cough</td><td class="xxxx-borders shading">44 (12.8)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">16 (4.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Vomiting</td><td class="xxxx-borders">43 (12.5)</td><td class="xxxx-borders">4 (1.2)</td><td class="xxxx-borders">12 (3.5)</td><td class="xxxr-borders">2 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypothyroidism</td><td class="xxxx-borders shading">40 (11.6)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">2 (0.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rash</td><td class="xxxx-borders">40 (11.6)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">4 (1.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">39 (11.3)</td><td class="xxxx-borders shading">13 (3.8)</td><td class="xxxx-borders shading">23 (6.7)</td><td class="xxxr-borders shading">10 (2.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hematuria</td><td class="xxxx-borders">36 (10.5)</td><td class="xxxx-borders">6 (1.7)</td><td class="xxxx-borders">37 (10.7)</td><td class="xxxr-borders">5 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Infusion-related reaction</td><td class="xbxx-borders shading">35 (10.2)</td><td class="xbxx-borders shading">3 (0.9)</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The safety population included all the patients in the avelumab group who received at least one dose of avelumab and all the patients in the control group who completed the cycle 1, day 1, visit. Shown are the adverse events of any grade and from any cause that occurred in at least 10% of these patients and the adverse events of grade 3 or higher and from any cause that occurred in at least 5% of these patients.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events (Safety Population).<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002788_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2002788</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer, version 3. 2020 (<a href="https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf">https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=National+Comprehensive+Cancer+Network.+Clinical+practice+guidelines+in+oncology%3A+bladder+cancer%2C+version+3.+2020+%28https%3A%2F%2Fwww.nccn.org%2Fprofessionals%2Fphysician_gls%2FPDF%2Fbladder.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. <em>J Clin Oncol</em> 2000;18:3068-3077.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2000.18.17.3068" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11001674/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000089038300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gemcitabine+and+cisplatin+versus+methotrexate%2C+vinblastine%2C+doxorubicin%2C+and+cisplatin+in+advanced+or+metastatic+bladder+cancer%3A+results+of+a+large%2C+randomized%2C+multinational%2C+multicenter%2C+phase+III+study.&amp;publication_year=2000&amp;journal=J+Clin+Oncol&amp;pages=3068-3077&amp;doi=10.1200%2FJCO.2000.18.17.3068&amp;pmid=11001674" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. <em>J Clin Oncol</em> 2005;23:4602-4608.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2005.07.757" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16034041/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230872000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+survival+results+of+a+randomized+trial+comparing+gemcitabine+plus+cisplatin%2C+with+methotrexate%2C+vinblastine%2C+doxorubicin%2C+plus+cisplatin+in+patients+with+bladder+cancer.&amp;publication_year=2005&amp;journal=J+Clin+Oncol&amp;pages=4602-4608&amp;doi=10.1200%2FJCO.2005.07.757&amp;pmid=16034041" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Dogliotti L, Cartenì G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. <em>Eur Urol</em> 2007;52:134-141.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2006.12.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17207911/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000247281400023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gemcitabine+plus+cisplatin+versus+gemcitabine+plus+carboplatin+as+first-line+chemotherapy+in+advanced+transitional+cell+carcinoma+of+the+urothelium%3A+results+of+a+randomized+phase+2+trial.&amp;publication_year=2007&amp;journal=Eur+Urol&amp;pages=134-141&amp;doi=10.1016%2Fj.eururo.2006.12.029&amp;pmid=17207911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. <em>J Clin Oncol</em> 2012;30:191-199.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.37.3571" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22162575/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302619000021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+phase+II%2FIII+trial+assessing+gemcitabine%2Fcarboplatin+and+methotrexate%2Fcarboplatin%2Fvinblastine+in+patients+with+advanced+urothelial+cancer+who+are+unfit+for+cisplatin-based+chemotherapy%3A+EORTC+study+30986.&amp;publication_year=2012&amp;journal=J+Clin+Oncol&amp;pages=191-199&amp;doi=10.1200%2FJCO.2011.37.3571&amp;pmid=22162575" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. <em>ScientificWorldJournal</em> 2018;2018:5682078-5682078.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1155/2018/5682078" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29977169/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+the+treatment+of+metastatic+urothelial+carcinoma.&amp;publication_year=2018&amp;journal=ScientificWorldJournal&amp;pages=5682078-5682078&amp;doi=10.1155%2F2018%2F5682078&amp;pmid=29977169" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Grivas P, Monk BJ, Petrylak D, et al. Immune checkpoint inhibitors as switch or continuation maintenance therapy in solid tumors: rationale and current state. <em>Target Oncol</em> 2019;14:505-525.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11523-019-00665-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31535338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000490952700002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+checkpoint+inhibitors+as+switch+or+continuation+maintenance+therapy+in+solid+tumors%3A+rationale+and+current+state.&amp;publication_year=2019&amp;journal=Target+Oncol&amp;pages=505-525&amp;doi=10.1007%2Fs11523-019-00665-1&amp;pmid=31535338" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] has been shown to prolong overall survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] cross-resistance and cumulative toxicity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Grivas PD, Daignault S, Tagawa ST, et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <em>Cancer</em> 2014;120:692-701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.28477" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24249435/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000331454200010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Double-blind%2C+randomized%2C+phase+2+trial+of+maintenance+sunitinib+versus+placebo+after+response+to+chemotherapy+in+patients+with+advanced+urothelial+carcinoma.&amp;publication_year=2014&amp;journal=Cancer&amp;pages=692-701&amp;doi=10.1002%2Fcncr.28477&amp;pmid=24249435" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Powles T, Huddart RA, Elliott T, et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. <em>J Clin Oncol</em> 2017;35:48-55.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2015.66.3468" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28034079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391381300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+III%2C+double-blind%2C+randomized+trial+that+compared+maintenance+lapatinib+versus+placebo+after+first-line+chemotherapy+in+patients+with+human+epidermal+growth+factor+receptor+1%2F2-positive+metastatic+bladder+cancer.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=48-55&amp;doi=10.1200%2FJCO.2015.66.3468&amp;pmid=28034079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">García-Donas J, Font A, Pérez-Valderrama B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. <em>Lancet Oncol</em> 2017;18:672-681.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30242-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28389316/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400401100055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+therapy+with+vinflunine+plus+best+supportive+care+versus+best+supportive+care+alone+in+patients+with+advanced+urothelial+carcinoma+with+a+response+after+first-line+chemotherapy+%28MAJA%3B+SOGUG+2011%2F02%29%3A+a+multicentre%2C+randomised%2C+controlled%2C+open-label%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=672-681&amp;doi=10.1016%2FS1470-2045%2817%2930242-5&amp;pmid=28389316" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Rosenberg JE, Ballman KV, Halabi S, et al. CALGB 90601 (Alliance): randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. <em>J Clin Oncol</em> 2019;37:Suppl:4503-4503. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.15_suppl.4503" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000487345805330" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CALGB+90601+%28Alliance%29%3A+randomized%2C+double-blind%2C+placebo-controlled+phase+III+trial+comparing+gemcitabine+and+cisplatin+with+bevacizumab+or+placebo+in+patients+with+metastatic+urothelial+carcinoma.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=4503-4503&amp;doi=10.1200%2FJCO.2019.37.15_suppl.4503" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. <em>Curr Opin Oncol</em> 2015;27:191-200.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCO.0000000000000177" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25811346/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352650300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emerging+immunotherapies+for+bladder+cancer.&amp;publication_year=2015&amp;journal=Curr+Opin+Oncol&amp;pages=191-200&amp;doi=10.1097%2FCCO.0000000000000177&amp;pmid=25811346" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <em>Nature</em> 2018;554:544-548.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature25501" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29443960/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425597400050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TGF%CE%B2+attenuates+tumour+response+to+PD-L1+blockade+by+contributing+to+exclusion+of+T+cells.&amp;publication_year=2018&amp;journal=Nature&amp;pages=544-548&amp;doi=10.1038%2Fnature25501&amp;pmid=29443960" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Stenehjem DD, Tran D, Nkrumah MA, Gupta S. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. <em>Onco Targets Ther</em> 2018;11:5973-5989.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/OTT.S135157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30275703/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445039400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD1%2FPDL1+inhibitors+for+the+treatment+of+advanced+urothelial+bladder+cancer.&amp;publication_year=2018&amp;journal=Onco+Targets+Ther&amp;pages=5973-5989&amp;doi=10.2147%2FOTT.S135157&amp;pmid=30275703" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <em>Lancet</em> 2018;391:748-757.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)33297-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29268948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426054000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+chemotherapy+in+patients+with+platinum-treated+locally+advanced+or+metastatic+urothelial+carcinoma+%28IMvigor211%29%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=748-757&amp;doi=10.1016%2FS0140-6736%2817%2933297-X&amp;pmid=29268948" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the context of second-line therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <em>Lancet</em> 2016;387:1909-1920.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00561-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26952546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375374200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+in+patients+with+locally+advanced+and+metastatic+urothelial+carcinoma+who+have+progressed+following+treatment+with+platinum-based+chemotherapy%3A+a+single-arm%2C+multicentre%2C+phase+2+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1909-1920&amp;doi=10.1016%2FS0140-6736%2816%2900561-4&amp;pmid=26952546" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] among patients with PD-L1–negative tumors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <em>Lancet Oncol</em> 2018;19:51-64.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30900-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29217288/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419018200054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab+in+metastatic+urothelial+carcinoma+after+platinum+failure+%28JAVELIN+Solid+Tumor%29%3A+pooled+results+from+two+expansion+cohorts+of+an+open-label%2C+phase+1+trial.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=51-64&amp;doi=10.1016%2FS1470-2045%2817%2930900-2&amp;pmid=29217288" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the overall survival at 2 years was 20.1%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] among patients with PD-L1–negative tumors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. <em>J Clin Oncol</em> 2017;35:2117-2124.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.6795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28375787/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404378800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab%2C+an+anti%E2%80%93programmed+death-ligand+1+antibody%2C+in+patients+with+refractory+metastatic+urothelial+carcinoma%3A+results+from+a+multicenter%2C+phase+Ib+study.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=2117-2124&amp;doi=10.1200%2FJCO.2016.71.6795&amp;pmid=28375787" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] among patients with PD-L1–negative tumors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <em>Lancet Oncol</em> 2016;17:1590-1598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(16)30496-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27733243/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000389537600051" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+monotherapy+in+recurrent+metastatic+urothelial+carcinoma+%28CheckMate+032%29%3A+a+multicentre%2C+open-label%2C+two-stage%2C+multi-arm%2C+phase+1%2F2+trial.&amp;publication_year=2016&amp;journal=Lancet+Oncol&amp;pages=1590-1598&amp;doi=10.1016%2FS1470-2045%2816%2930496-X&amp;pmid=27733243" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <em>Lancet Oncol</em> 2017;18:312-322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30065-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28131785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396344600043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+in+metastatic+urothelial+carcinoma+after+platinum+therapy+%28CheckMate+275%29%3A+a+multicentre%2C+single-arm%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=312-322&amp;doi=10.1016%2FS1470-2045%2817%2930065-7&amp;pmid=28131785" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. <em>JAMA Oncol</em> 2017;3(9):e172411-e172411.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaoncol.2017.2411" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28817753/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410676400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+durvalumab+in+locally+advanced+or+metastatic+urothelial+carcinoma%3A+updated+results+from+a+phase+1%2F2+open-label+study.&amp;publication_year=2017&amp;journal=JAMA+Oncol&amp;pages=e172411-e172411&amp;doi=10.1001%2Fjamaoncol.2017.2411&amp;pmid=28817753" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] among patients with PD-L1–negative tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] tumors, would undergo randomization. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. <em>N Engl J Med</em> 2017;376:1015-1026.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002788&amp;key=10.1056%2FNEJMoa1613683&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28212060/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396403700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+as+second-line+therapy+for+advanced+urothelial+carcinoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1015-1026&amp;doi=10.1056%2FNEJMoa1613683&amp;pmid=28212060" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] candidates for platinum-based therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the context of second-line therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &gt;2 years of follow-up. <em>Ann Oncol</em> 2019;30:970-976.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz127" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31050707/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479284000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+phase+III+KEYNOTE-045+trial+of+pembrolizumab+versus+paclitaxel%2C+docetaxel%2C+or+vinflunine+in+recurrent+advanced+urothelial+cancer%3A+results+of+%3E2+years+of+follow-up.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=970-976&amp;doi=10.1093%2Fannonc%2Fmdz127&amp;pmid=31050707" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <em>Lancet Oncol</em> 2017;18:1483-1492.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30616-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28967485/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414134100055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+pembrolizumab+in+cisplatin-ineligible+patients+with+locally+advanced+and+unresectable+or+metastatic+urothelial+cancer+%28KEYNOTE-052%29%3A+a+multicentre%2C+single-arm%2C+phase+2+study.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=1483-1492&amp;doi=10.1016%2FS1470-2045%2817%2930616-2&amp;pmid=28967485" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <em>Lancet</em> 2017;389:67-76.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)32455-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27939400/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391264000039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+as+first-line+treatment+in+cisplatin-ineligible+patients+with+locally+advanced+and+metastatic+urothelial+carcinoma%3A+a+single-arm%2C+multicentre%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=67-76&amp;doi=10.1016%2FS0140-6736%2816%2932455-2&amp;pmid=27939400" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Gupta S, Sonpavde G, Grivas P, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). <em>J Clin Oncol</em> 2019;37:Suppl:451-451. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.7_suppl.451" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489108800467" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+%E2%80%9Cplatinum-ineligible%E2%80%9D+patients+with+metastatic+urothelial+cancer+%28mUC%29.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=451-451&amp;doi=10.1200%2FJCO.2019.37.7_suppl.451" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Szabados B, van Dijk N, Tang YZ, et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. <em>Eur Urol</em> 2018;73:149-152.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2017.08.022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28917596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419708200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+rate+to+chemotherapy+after+immune+checkpoint+inhibition+in+metastatic+urothelial+cancer.&amp;publication_year=2018&amp;journal=Eur+Urol&amp;pages=149-152&amp;doi=10.1016%2Fj.eururo.2017.08.022&amp;pmid=28917596" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Sonpavde GP, Mariani L, Lo Vullo S, et al. Impact of the number of cycles of platinum based first line chemotherapy for advanced urothelial carcinoma. <em>J Urol</em> 2018;200:1207-1214.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.juro.2018.07.035" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30012366/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449558500074" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+the+number+of+cycles+of+platinum+based+first+line+chemotherapy+for+advanced+urothelial+carcinoma.&amp;publication_year=2018&amp;journal=J+Urol&amp;pages=1207-1214&amp;doi=10.1016%2Fj.juro.2018.07.035&amp;pmid=30012366" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. <em>J Clin Oncol</em> 2020;38:1797-1806.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.03091" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32271672/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537770500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+double-blind+phase+II+study+of+maintenance+pembrolizumab+versus+placebo+after+first-line+chemotherapy+in+patients+with+metastatic+urothelial+cancer.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=1797-1806&amp;doi=10.1200%2FJCO.19.03091&amp;pmid=32271672" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Apolo AB, Ellerton JA, Infante JR, et al. Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: updated safety and efficacy analysis with ≥ two-years of follow-up. <em>J Clin Oncol</em> 2019;37:Suppl:425-425. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.7_suppl.425" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489108800441" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab+treatment+for+metastatic+urothelial+carcinoma+in+the+phase+Ib+JAVELIN+Solid+Tumor+Study%3A+updated+safety+and+efficacy+analysis+with+%E2%89%A5+two-years+of+follow-up.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=425-425&amp;doi=10.1200%2FJCO.2019.37.7_suppl.425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Zajac M, Boothman A-M, Ben Y, et al. Analytical validation and clinical utility of an immunohistochemical programmed death ligand-1 diagnostic assay and combined tumor and immune cell scoring algorithm for durvalumab in urothelial carcinoma. <em>Arch Pathol Lab Med</em> 2019;143:722-731.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5858/arpa.2017-0555-OA" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30457897/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000468925700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analytical+validation+and+clinical+utility+of+an+immunohistochemical+programmed+death+ligand-1+diagnostic+assay+and+combined+tumor+and+immune+cell+scoring+algorithm+for+durvalumab+in+urothelial+carcinoma.&amp;publication_year=2019&amp;journal=Arch+Pathol+Lab+Med&amp;pages=722-731&amp;doi=10.5858%2Farpa.2017-0555-OA&amp;pmid=30457897" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <em>Lancet</em> 2020;395:1547-1557.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r32-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30230-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536542900021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+with+or+without+chemotherapy+in+metastatic+urothelial+cancer+%28IMvigor130%29%3A+a+multicentre%2C+randomised%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1547-1557&amp;doi=10.1016%2FS0140-6736%2820%2930230-0&amp;pmid=32416780" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r32-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for advanced urothelial carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] NCT04223856]). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] placebo, in patients with advanced disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] hazard ratio, 0.91; 95% CI, 0.74 to 1.14). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. Press release of the Food and Drug Administration, updated August 16, 2018 (<a href="https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm">https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=FDA+alerts+health+care+professionals+and+oncology+clinical+investigators+about+an+efficacy+issue+identified+in+clinical+trials+for+some+patients+taking+Keytruda+%28pembrolizumab%29+or+Tecentriq+%28atezolizumab%29+as+monotherapy+to+treat+urothelial+cancer+with+low+expression+of+PD-L1.+Press+release+of+the+Food+and+Drug+Administration%2C+updated+August+16%2C+2018+%28https%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm608075.htm%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Schwamborn K, Ammann JU, Knüchel R, et al. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. <em>Virchows Arch</em> 2019;475:599-608.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00428-019-02610-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31267201/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000497269100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multicentric+analytical+comparability+study+of+programmed+death-ligand+1+expression+on+tumor-infiltrating+immune+cells+and+tumor+cells+in+urothelial+bladder+cancer+using+four+clinically+developed+immunohistochemistry+assays.&amp;publication_year=2019&amp;journal=Virchows+Arch&amp;pages=599-608&amp;doi=10.1007%2Fs00428-019-02610-z&amp;pmid=31267201" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Eckstein M, Erben P, Kriegmair MC, et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <em>Eur J Cancer</em> 2019;106:234-243.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2018.11.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30528808/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453243400026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Performance+of+the+Food+and+Drug+Administration%2FEMA-approved+programmed+cell+death+ligand-1+assays+in+urothelial+carcinoma+with+emphasis+on+therapy+stratification+for+first-line+use+of+atezolizumab+and+pembrolizumab.&amp;publication_year=2019&amp;journal=Eur+J+Cancer&amp;pages=234-243&amp;doi=10.1016%2Fj.ejca.2018.11.007&amp;pmid=30528808" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Zajac M, Scott M, Ratcliffe M, et al. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. <em>Diagn Pathol</em> 2019;14:99-99.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13000-019-0873-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31477145/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000483507600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Concordance+among+four+commercially+available%2C+validated+programmed+cell+death+ligand-1+assays+in+urothelial+carcinoma.&amp;publication_year=2019&amp;journal=Diagn+Pathol&amp;pages=99-99&amp;doi=10.1186%2Fs13000-019-0873-6&amp;pmid=31477145" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS. The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. <em>Eur Urol</em> 2019;75:435-444.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2018.09.022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30274701/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458490100031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+cancer+immunogram+as+a+framework+for+personalized+immunotherapy+in+urothelial+cancer.&amp;publication_year=2019&amp;journal=Eur+Urol&amp;pages=435-444&amp;doi=10.1016%2Fj.eururo.2018.09.022&amp;pmid=30274701" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <em>Ther Clin Risk Manag</em> 2018;14:1019-1040.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/TCRM.S158753" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29892196/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434035900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+checkpoint+inhibitors+in+urothelial+cancer%3A+recent+updates+and+future+outlook.&amp;publication_year=2018&amp;journal=Ther+Clin+Risk+Manag&amp;pages=1019-1040&amp;doi=10.2147%2FTCRM.S158753&amp;pmid=29892196" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 16, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2032018" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Avelumab Maintenance for Urothelial Carcinoma</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Rockport, Maine</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885467/physician-urologist-in-beautiful-rockport-maine/?query=fjwp&amp;rid=1000">Physician, Urologist in Beautiful Rockport, Maine</a></div></div><div class="nejm-widget_item"><div><span> Riverhead, New York</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893424/associate-program-director-at-the-family-medicine-residency-program-at-peconic-bay-medical-center/?query=fjwp&amp;rid=3059">Associate Program Director at the Family Medicine Residency Program at Peconic Bay Medical Center</a></div></div><div class="nejm-widget_item"><div><span> Edmonds, Washington State</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881613/primary-care-physician/?query=fjwf&amp;rid=6691">Primary Care Physician</a></div></div><div class="nejm-widget_item"><div><span> Virginia</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883490/pediatric-hospitalist/?query=fjwf&amp;rid=49812">Pediatric Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> California</span></div><div><span>Cardiology / Interventional</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890152/interventional-cardiology-in-monterey-bay-area-ca-100k-recruitment-incentive/?query=fjwf&amp;rid=5263">Interventional Cardiology in Monterey Bay Area, CA | 100k Recruitment Incentive</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887001/hematology-oncology-1-hour-from-houston-tx-large-hospital-association/?query=fjwf&amp;rid=5263">Hematology Oncology | 1 Hour from Houston, TX | Large Hospital Association</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2002788&amp;pubId=41289170&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d64a8083a901a6-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d64a8083a901a6-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d64a8083a901a6-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$187068743$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$187068743$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$187068743$--></div></div><div class="mlt-body"><!--?lit$187068743$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$187068743$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$187068743$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$187068743$-->Nov 09, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2309863?query=recirc_Semantic" target="_self">Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$187068743$-->M.S. van der Heijden and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$187068743$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$187068743$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$187068743$-->Mar 07, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312117?query=recirc_Semantic" target="_self">Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer</a></div><div class="mlt-article-authors"><!--?lit$187068743$-->T. Powles and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$187068743$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$187068743$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$187068743$-->Mar 07, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2400311?query=recirc_Semantic" target="_self">Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer</a></div><div class="mlt-article-authors"><!--?lit$187068743$-->G. Niegisch</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$187068743$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$187068743$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$187068743$-->Jan 02, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401726?query=recirc_Semantic" target="_self">Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$187068743$-->A.B. Apolo and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$187068743$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$187068743$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$187068743$-->Nov 23, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2308849?query=recirc_Semantic" target="_self">Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$187068743$-->Y. Loriot and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2002788?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2002788" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2002788.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2002788"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1917239" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1915905" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Lower-Dose Zinc for Childhood Diarrhea — A Randomized, Multicenter Trial</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f1.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/a2d2c49d-075d-4dc9-862c-b393d6f5dc20/assets/images/large/nejmoa2002788_f1.jpg" height="2771" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival in the Overall Population and the PD-L1–Positive Population.</div><div class="notes"><div role="doc-footnote">Patients in the avelumab group received avelumab and best supportive care, and patients in the control group received best supportive care alone. Tick marks indicate censored data. NE denotes could not be estimated, and PD-L1 programmed cell death ligand 1.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002788_f2.jpg"><img src="/cms/10.1056/NEJMoa2002788/asset/5e2f1004-896a-4924-9752-05e52da8baa5/assets/images/large/nejmoa2002788_f2.jpg" height="2772" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Progression-free Survival in the Overall Population and the PD-L1–Positive Population.</div><div class="notes"><div role="doc-footnote">Progression was assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Tick marks indicate censored data.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Responses in the Overall Population and the PD-L1–Positive Population.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events (Safety Population).<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/13" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 13</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 24, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1917239" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.S. Hong and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 24, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1915905" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Lower-Dose Zinc for Childhood Diarrhea — A Randomized, Multicenter Trial</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">U. Dhingra and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 24, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1915035" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.M. Cohn and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2002788%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2002788&amp;pubId=41289170&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2002788%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2002788&amp;pubId=41289170&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id043094667382123597" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d64a8083a901a6-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d64a8083a901a6-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d64a8083a901a6-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d64a8083a901a6-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d64a8083a901a6-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d64a8083a901a6-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d64a8083a901a6-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d64a8083a901a6-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d64a8083a901a6-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d64a8083a901a6-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d64a806a0601a6',t:'MTc0OTUzMTQ3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d64a806a0601a6&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><jcu-rsqduwxityhv></jcu-rsqduwxityhv><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2002788?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-transactionid="4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" id="captureIFrame_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" target="captureIFrame_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="capture_screen"><input id="capture_signIn_js_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="js_version"><input id="capture_signIn_transactionId_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" type="hidden" class="capture_transactionId_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="capture_transactionId"><input id="capture_signIn_form_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="form"><input id="capture_signIn_flow_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="flow"><input id="capture_signIn_client_id_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="client_id"><input id="capture_signIn_redirect_uri_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="redirect_uri"><input id="capture_signIn_response_type_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="response_type"><input id="capture_signIn_flow_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="flow_version"><input id="capture_signIn_settings_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="settings_version"><input id="capture_signIn_locale_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="locale"><input id="capture_signIn_recaptcha_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_4vnb2mnolb4jmvh2zai4xwrfk6ze8mjne0kdgdnh" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>